小児血液・腫瘍学　改訂第2版

第I部 総論

P.5 掲載の参考文献

1) Doulatov S, et al. : Hematopoiesis : a human perspective. Cell Stem Cell 10 : 120-136, 2012

PubMed

2) Coskun S, et al. : Establishment and regulation of the hsc niche : roles of osteoblastic and vascular compartment. Birth Defects Res C Embroy Today 90 : 229-242, 2010

 

3) Miller JL. : Hemoglobin switching and modulation : genes, cells, and signals. Curr Opin Hematol 9 : 87-92, 2002

PubMed

4) Wilson A, et al. : Dormant and Self-Renewing Hematopoietic Stem Cells and Their Niches. Ann NY Acad Sci 1106 : 64-75, 2007

PubMed

5) Saito Y, et al. : Understanding normal and malignant human hematopoiesis using next-generation humanized mice. Trends Immunol 41 : 706-720, 2020

PubMed

6) Kumar S, et al. : HSC niche biology and hsc expansion ex vivo. Trends Mol Med 23 : 799-819, 2017

PubMed

7) Pinho S, et al. : Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol 20 : 303-320, 2019

PubMed

P.11 掲載の参考文献

1) 矢田純一 : 医系免疫学 改訂15版. 中外医学社, 2018

 

2) Murphy k, et al. (eds.) : Janeway's immunobiology. 7th ed. Garland Science, 2008

 

3) 菅村和夫, 他 (編) : サイトカイン・増殖因子用語ライブラリー. 羊土社, 2005

 

P.13 掲載の参考文献

1) Keller G : Embryonic stem cell differentiation : emergence of a new era in biology and medicine. Genes Dev 19 : 1129-1155, 2005

 

2) Karagiannis P, et al. : Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev 99 : 79-114, 2019

PubMed

3) Yamanaka S : Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1 : 39-49, 2007

PubMed

4) Wang Y, et al. : Embryonic stem-cell derived hematopoietic stem cells. Proc Natl Acad Sci USA 102 : 19081-19086, 2005

PubMed

P.15 掲載の参考文献

Carmel R, et al. : Megaloblastic anemia. In : Orkin SH, et al. (eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed, Elsevier, 308-343, 2015

 

Fleming MD, et al. : Disorders of iron and copper Metabolism, the sideroblastic anemias, and lead toxicity. In : Orkin SH, et al. (eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed, Elsevier, 344-381, 2015

 

Pasricha SR, et al. : Iron deficiency. Lancet 397 : 233-248, 2021

PubMed

P.18 掲載の参考文献

浅野茂隆, 他 (監) : 三輪血液病学. 第3版, 文光堂, 2006

 

三輪史朗, 他 (編) : 血液細胞アトラス. 第5版, 文光堂, 2004

 

Means RT Jr, et al. : Wintrobe's Clinical Hematology. 13th ed, LWW, 2013

 

Orkin SH, et al. : Nathan and Oski's Hematology of Infancy and Childhood. 7th ed, Saunders, 2008

 

P.22 掲載の参考文献

1) Avecilla ST, et al. : Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Medicine 10 : 64-71, 2004

 

2) Thon JN, et al. : Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 191 : 861-874, 2010

PubMed

3) 國島伸治 : 先天性血小板減少症. 臨血 59 : 764-773, 2018

 

4) Berndt MC, et al. : Primary haemostasis : newer insights. Haemophilia 4 : 15-22, 2014

 

P.24 掲載の参考文献

1) Abbas AK, et al. : Cells and Tissues of the Immune System. In : Cellular and Molecular Immunology. 9th ed, Elevier Saunders, 13-37, 2017

 

P.27 掲載の参考文献

1) Dougald M, et al. : Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In : Kaushansky K, et al. (eds.), Williams Hematology. 8th ed, McGraw-Hill Global Education, 1815-1843, 2010

 

2) Katherine A, et al. : Fibrinolysis and thrombolysis. In : Kaushansky K, et al. (eds.), Williams Hematology. 8th ed, McGraw-Hill Global Education, 2219-2244, 2010

 

3) Burmmel Ziedins K, et al. : Blood coagulation and fibrinolysis. In : Greer JP, et al. (eds.), Wintrobe's Clinical hematology. Lippincott Williams & Wilkins, 677-774, 2003

 

4) Monagle P, et al. : Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 95 : 362-372, 2006

PubMed

P.29 掲載の参考文献

1) 総務省統計局 : 人口推計 2021年4月報, 2021 https://www.stat.go.jp/data/jinsui/pdf/202104.pdf (2021年5月閲覧)

 

2) 日本小児血液・がん学会 : 疾患登録集計結果, 2018 https://www.jspho.org/syoni_login/pdf/2018.pdf (2021年5月閲覧)

 

3) 国立がん研究センターがん情報サービス : がん登録・統計 : 小児・AYA世代のがん罹患 https://ganjoho.jp/reg_stat/statistics/stat/child_aya.html (2021年5月閲覧

 

P.32 掲載の参考文献

Brugnara C, et al. : Diagnostic approach to the anemic patient. In : Orkin SH, et al. (eds.), Nathan and Oski's Hematology and Oncology of Infancy and Childhood. 8th ed, Elsevier, 293-307, 2015

 

P.34 掲載の参考文献

石黒精, 他 : 先天性血小板減少症・異常症の新しい診断・登録・検体保存体制. 日小児血がん会誌 57 : 227-234, 2020

Medical*Online

石黒精, 他 : 小児科で遭遇する血栓性疾患. 血栓止血の臨床-研修医のために (改訂版). 日血栓止血会誌 30 : 9-13, 2019

 

P.37 掲載の参考文献

1) Butler EM, et al. : Cervical lymphadenitis. In : Feigin RD, et al. (eds.), Feigin and Cherry's Textbook of Pediatric Infectious Disease. 4th ed, WB Saunders, 170-180, 1998

 

2) Lang S, et al. : Cervical lymph node diseases in children. GMS Curr Top Otorhinolaryngol Head Neck Surg 13 : Doc 08, doi : 10.3205/cto000111, 2014

 

3) Meier JD, et al. : Evaluation and management of neck masses in children. Am Fam Physician 89 : 353-358, 2014

PubMed

4) Green M : The abdomen. In : Green M (eds.), Pediatric diagnosis. 5th ed, WB Saunders, 83-96, 1992

 

5) 二村貢 : 脾臓のエコー検査. 小児診療 59 : 649-654, 1996

Medical*Online

P.39 掲載の参考文献

1) 厚生労働省原発性免疫不全症候群調査研究班 (編) : 原発性免疫不全症を疑う10の徴候-患者・プライマリーケア医師へ向けて (2010年改訂). http://pidj.rcai.riken.jp/10warning_signs.html〔2021年4月アクセス〕

 

2) Tangye SG, et al. : Human inborn errors of immunity : 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol 40 : 24-64, 2020

 

3) 症例相談 (医師専用). 日本免疫不全・自己炎症学会 https://www.jsiad.org/ 〔2021年4月アクセス〕

 

P.42 掲載の参考文献

1) Bain BJ : Diagnosis from the blood smear. N Engl J Med 4 : 353 : 498-507, 2005

 

2) 別所文雄 : 血液標本の見方. 日小血会誌 22 : 2331-2339, 2008

 

3) 三輪史朗, 他 : 血液細胞アトラス 第4版. 文光堂, 1990

 

4) 朝長万佐男, 他 (編) : 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 2008

 

P.44 掲載の参考文献

1) Monagle P, et al. : Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb haemost 95 : 362?372, 2006

 

P.46 掲載の参考文献

1) 金子誠 : 臨床検査から見た血栓・止血疾患の診断. 臨血 55 : 874-881, 2014

 

2) Kunishima S, et al. : Bernard-Soulier syndrome due to GPIX W127X mutation in Japan is frequently misdiagnosed as idiopathic thrombocytopenic purpura. Int J Hematol 83 : 366-367, 2006

PubMed

P.49 掲載の参考文献

1) 森尾友宏 : 原発性免疫不全症関連検査, 三橋知明, Medical Practice編集委員会 (編), 臨床検査ガイド. 文光堂, 773-778, 2015

 

2) 森尾友宏 : NK細胞活性. 三橋知明, Medical Practice編集委員会 (編), 臨床検査ガイド. 文光堂 785-787, 2015

 

3) 森尾友宏 : 検査値を読む 2013 細胞性免疫検査 リンパ球サブセット検査. 内科 111 : 1404, 2013

 

P.51 掲載の参考文献

1) 三輪史朗, 他 : 血液細胞アトラス. 第4版, 文光堂, 1990

 

2) 張替秀郎 : 遺伝性鉄芽球性貧血の病態と診断. 日小児血液会誌 25 : 118-122, 2011

Medical*Online

3) 別所文雄 : 血液標本の見方. 日小血会誌 22 : 331-339, 2008

 

4) Swerdlow SH, et al. (eds.) : WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC press, 2008

 

5) 伊藤雅文 : 小児造血不全症の病理中央診断. 臨血 58 : 661-668, 2017

 

P.55 掲載の参考文献

1) 平石佳之 : G 分染法. 古庄敏行 監修・編集, 臨床染色体診断法. 金原出版, 103-106, 1996

 

2) 西田一弘 : 造血器腫瘍の診療におけるspectral karyotyping法. 谷脇雅史, 他 (編著), 造血器腫瘍アトラス形態, 免疫, 染色体から分子細胞治療へ 第5版. 日本医事新報, 127-134, 2016

 

3) 滝智彦, 他 : 細胞遺伝学的および分子生物学的診断. 堀部敬三, 他 (編), 小児造血器腫瘍の診断の手引き. 日本医学館, 33-45, 2012

 

4) McGowan-Jordan J, et al. (eds.) : ISCN 20202 : An international System for Human Cytogenetic Nomenclature (2020). Karger, 2020

 

5) Gardner RJM, et al. : Variant Chromosomes and Abnormalities of No Phenotypic Consequence. In : Chromosome abnormalities and genetic counseling, 5th ed. Oxford University Press, 369-384, 2018

 

6) 滝智彦 : 染色体検査における個人遺伝情報管理. Lab Clin Pract 32 : 5-8, 2014

Medical*Online

7) 国立大学法人京都大学大学院医学研究科, 国立研究開発法人日本医療研究開発機構 : 「ゲノム医療における情報伝達プロセスに関する提言-その1 : がん遺伝子パネル検査を中心に (改定第2版) 」及び「ゲノム医療における情報伝達プロセスに関する提言-その2 : 次世代シークエンサーを用いた生殖細胞系列網羅的遺伝学的検査における具体的方針 (改定版) 」の公開 https://www.amed.go.jp/news/seika/kenkyu/20200121.html

 

P.58 掲載の参考文献

1) Sugimori C, et al. : Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 : 1308-1314, 2006

PubMed

2) Sakaguchi H, et al. : Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica 99 : 1312-1316, 2014

PubMed

3) Miwata S, et al. : Clinical diagnostic. value of telomere length measurement in inherited bone marrow failure syndromes. Haematologica 2021 Apr 22. Online ahead of print

 

4) Shimamura A, et al. : A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100 : 4649-4654, 2002

PubMed

P.60 掲載の参考文献

1) 石村匡崇, 他 : 先天性骨髄不全症候群と原発性免疫不全症におけるがん素因. 臨血 60 : 702-707, 2019

 

2) Quon D, et al. : Unmet needs in the transition to adulthood : 18- to 30-year old people with hemophilia. Am J Hematol 90 : S17-S22, 2015

PubMed

3) Yacobovich J, et al. : Thalassemia major and sickle cell disease in adolescents and young adults. Acta Haematol 132 : 340-347, 2014

 

4) Saulsberry AC, et al. : A program of transition to adult care for sickle cell disease. Hematology Am Soc Hematol Educ Program 1 : 496-504, 2019

PubMed

5) 日本産婦人科・新生児血液学会 (編) : 産婦人科・新生児領域の血液疾患 診療の手引き. メジカルビュー, 2017

 

P.64 掲載の参考文献

1) 石井栄三郎 : 小児がん-1. 小児がんの疫学と発生要因-. 小児口腔外 19 : 1-13, 2009

Medical*Online

2) Johnston WT, et al. : Childhood cancer : Estimating regional and global incidence. Cancer Epidemiol 71 : 101662, 2021. doi : 10.1016/j.canep2019.101662

 

3) 国立がん研究センターがん情報サービス. https://ganjoho.jp/public/index.html

 

4) Kaatsch P : Epidemiology of childhood cancer. Cancer Treat Rev 36 : 277-285, 2010

PubMed

5) Linabery AM, et al. : Trends in Childhood Cancer Incidence in the U.S. (1992-2004). Cancer 112 : 416-432, 2008

 

日本小児血液・がん学会 : 疾患登録集計結果2014～2019年.

 

池田均 : 日本における小児がん登録の現状と将来 : 日本小児がん学会小児がん全数把握登録事業について. 日小児会誌 114 : 1497-1505, 2010

 

Steliarova-Foucher E, et al. : International Classification of Childhood Cancer, Third Edition. Cancer 103 : 1457-1467, 2005

PubMed

P.68 掲載の参考文献

1) Knudson AG : Hereditary predisposition to cancer. Ann N Y Acad Sci 833 : 58-67, 1997

PubMed

2) Marsh DJ, et al. : Genetic insights into familial cancers-update and recent discoveries. Cancer Lett 181 : 125-164, 2002

 

3) がん情報サービス : 最新がん統計 2015年度. 国立がん研究センターがん対策情報センター, 2015 http://ganjoho.jp/reg_stat/statistics/stat/summary.html

 

4) Li FP, et al. : A cancer family syndrome in twenty-four kindreds. Cancer Res 48 : 5358-5362, 1988

PubMed

5) Tinat J, et al. : 2009 version of the Chompret criteria for Li Fraumeni syndrome J Clin Oncol 27 : e108-e109, 2009

PubMed

6) Smith AR, et al. : Current clinical management of Fanconi anemia. Expert Rev Hematol 5 : 513-522, 2012

PubMed

7) van Leeuwaarde RS, et al. : Von Hippel-Lindau Syndrome. GeneReviews(R) [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK1463/

 

P.72 掲載の参考文献

1) Gu Z, et al. : PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 51 : 296-307, 2019

PubMed

2) Liu Y, et al. : The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49 : 1211-1218, 2017

 

3) Wright GW, et al. : A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37 : 551-568, 2020

PubMed

4) Mack SC, et al. : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-450, 2014

PubMed

堀部敬三 (編) : 小児がん診療ハンドブック, 医薬ジャーナル社, 2011

 

臨床研究情報センター : 小児 (治療). がん情報サイト｜PDQ(R) 日本語版, http://cancerinfo.tri-kobe.org/

 

日本小児血液・がん学会 (編) : 小児がん診療ガイドライン 2016年版, 金原出版, 2016

 

WHO classification of tumors of Haematopoietic and Lymphoid tissues, Lyon, IARC, 2017

 

P.75 掲載の参考文献

1) Hanahan D, et al. : The hallmarks of cancer. Cell 100 : 57-70, 2000

PubMed

2) Hanahan D, et al. : Hallmarks of cancer : the next generation. Cell 144 : 646-674, 2011

PubMed

3) Iacobucci I, et al. : Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 35 : 975-983, 2017

PubMed

4) Cheung N-K, et al. : Neuroblastoma : developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13 : 397-411, 2013

PubMed

5) Matthay KK, et al. : Neuroblastoma. Nat Rev Dis Primers 2 : 16078, 2016

PubMed

6) Bouaoun L, et al. : TP53 Variations in human cancers : new lessons from the IARC TP53 database and genomic data. Hum Mutat 37 : 865-876, 2016

PubMed

P.78 掲載の参考文献

1) Coiffier B, et al. : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J med 346 : 235-242, 2002

PubMed

2) Griffin TC, et al. : A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia : a report from the Children's Oncology Group. Pediatr blood cancer 52 : 177-181, 2009

 

3) Cheung NK, et al. : Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16 : 3053-3060, 1998

 

4) Simon T, et al. : Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22 : 3549-3557, 2004

PubMed

5) Yu AL, et al. : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363 : 1324-1334, 2010

PubMed

6) Kapoor A, et al. : Blinatumomab ; A ray of hope for relapsed/refractory adult B-cell acute lymphoblastic leukemia. Clinical Investigation Journal 3 : 577-578, 2014

 

7) Topp MS, et al. : Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia : a multicentre, single-arm, phase 2 study. Lancet Oncol 16 : 57-66, 2015

 

8) Ito A, et al. : Clinical Development of Immune Checkpoint Inhibitors. BioMed Res Int 2015 : 605478, 2015

PubMed

P.80 掲載の参考文献

1) Pui CH : Acute lymphoblastic leukemia. In : Pui CH (ed.), Childhood Leukemias. 3rd ed, Cambridge University Press, 332-336, 2012

 

2) Silverman LB, et al. : Acute lymphoblastic leukemia. In : Orkin SH, et al. Oncology of Infancy and Childhood. Saunders, 297-505, 2009

 

3) Lanzkowsky P et al. (eds.) : Lanzkowsky's Manual of Pediatric Hematology and Oncology. 6th ed, Elsevier, 367-452, 2016

 

4) 岡本康裕, 他 : 一次診療で小児がんを疑う症状・所見の検討. 第56回日本小児血液・がん学会学術集会, 2014.11.28～11.30

 

P.84 掲載の参考文献

1) Dang-Tan T, et al. : Diagnosis delays in childhood cancer : a review. Cancer 110 : 703-713, 2007

 

2) Bourdeaut F, et al. : VIP hypersecretion as primary or secondary syndrome in neuroblastoma : A retrospective study by the Societe Francaise des Cancers de l'Enfant (SFCE). Pediatr Blood Cancer 52 : 585-590, 2009

PubMed

3) Amar AM, et al. : Clinical presentation of rhabdoid tumors of the kidney. J Pediatr Hematol Oncol 23 : 105-108, 2001

PubMed

4) De Bernardi B, et al. : Epidural compression in neuroblastoma : Diagnostic and therapeutic aspects. Cancer Lett 228 : 283-299, 2005

PubMed

5) Matthay KK, et al. : Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 228 : 275-282, 2005

PubMed

6) Maas MH, et al. : Renin-induced hypertension in Wilms tumor patients. Pediatr Blood Cancer 48 : 500-503, 2007

PubMed

7) JS Dome, et al. : Wilms Tumor Overview. GeneReviews(R) [Internet]. Seattle Univ. Washington, Seattle ; 1993-2015 http://www.ncbi.nlm.nih.gov/books/NBK1294/

 

8) Brodeur GM, et al. : Pediatric cancer predisposition and surveillance : An Overview, and a Tribute to Alfred G. Knudson Jr. Clin Cancer Res 23 : e1-e5, 2017

 

9) Muto R, et al. : Prediction by FISH analysis of the occurrence of Wilms tumor in aniridia patients. Am J Med Genet 108 : 285-289, 2002

PubMed

10) Niemitz EL, et al. : Children with idiopathic hemihypertrophy and beckwith-wiedemann syndrome have different constitutional epigenotypes associated with wilms tumor. Am J Hum Genet 77 : 887-991, 2005

PubMed

11) Hoyme HE, et al. : Isolated hemihyperplasia (hemihypertrophy) : report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 79 : 274-278, 1998

PubMed

12) Sung L, et al. : Neurofibromatosis in children with Rhabdomyosarcoma : a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 144 : 666-668, 2004

 

13) Garber JE, et al. : Hepatoblastoma and familial adenomatous polyposis. J Natl Cancer Inst 80 : 1626-1628, 1988

PubMed

P.86 掲載の参考文献

1) Thorpe WP, et al. : Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43 : 2178-2181, 1979

PubMed

2) Link MP, et al. : Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 270 : 8-14, 1991

PubMed

3) WHO Classification of Tumours Editorial Board : WHO Classification of Tumours, 5th ed., Vol. 3 Soft Tissue & Bone Tumours, 2020

 

4) Widhe B, et al. : Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 82 : 667-674, 2000

PubMed

5) Cotterill SJ, et al. : Prognostic factors in Ewing's tumor of bone : analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 18 : 3108-3114, 2000

 

6) Rud NP, et al. : Extraosseous Ewing's sarcoma. A study of 42 cases. Cancer 64 : 1548-1553, 1989

PubMed

7) Crist W, et al. : The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13 : 610-630, 1995

PubMed

P.88 掲載の参考文献

1) The Committee of Brain Tumor Registry of Japan : REPORT OF BRAIN TUMOR REGISTRY OF JAPAN (2001-2004) 13th Edition. Neurol Med Chir (Tokyo) 54 (suppl.1) : 1-102, 2014

 

2) Wilne S, et al. : Presentation of childhood CNS tumours : a systematic review and meta-analysis. Lancet Oncol 8 : 685-695, 2007

PubMed

3) Yamada Y, et al. : Initial symptoms and diagnostic delay in children with brain tumors at a single institution in Japan. Neurooncol Pract 8 : 60-67, 2020

 

4) Crawford J : Childhood brain tumors. Pediatr Rev 43 : 63-78, 2013

 

P.90 掲載の参考文献

1) Tsuchida Y, et al. : Evaluation of alpha-fetoprotein in early infancy. J Pediatr Surg 13 : 155-156, 1978

PubMed

P.94 掲載の参考文献

1) Campana D, et al. : Immunophenotyping of leukemia. J Immunol Methods 243 : 59-75, 2000

PubMed

2) Iwamoto S, et al. : Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 94 : 185-192, 2011.

 

3) Ohta H, et al. : Flow cytometric analysis of de novo acute myeloid leukemia in childhood : report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 93 : 135-137, 2011

 

4) Swerdlow SH, et al. (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (World Health Organization Classification of Tumours). Revised 4th ed, volume 2, World Health Organization, 180-187, 2017

 

5) 出口隆生 : 混合型白血病 診断の現状と問題点. 血液フロンティア 20 : 343-349, 2010

 

P.97 掲載の参考文献

McGowan-Jordan J, et al. (eds) : ISCN2020 : An International System for Human Cytogenomic Nomenclature 2020. Karger, 2020

 

Imamura T : Genetic Alterations of Pediatric Acute Lymphoblastic Leukemia. In : Kato M (ed), Pediatric Acute Lymphoblastic Leukemia. Springer, 9-19, 2020

 

谷脇雅史, 他 (編著) : 造血器腫瘍アトラス 形態, 免疫, 染色体から分子細胞治療へ. 第5版, 日本医事新報社, 2016

 

P.100 掲載の参考文献

1) Ewin肉腫/原始神経外胚葉性腫瘍群. 日本病理学会小児腫瘍組織分類委員会 (編), 小児腫瘍組織カラーアトラス 第3巻 骨軟部腫瘍. 金原出版, 33-34, 2005

 

2) ホルマリン固定パラフィン包埋組織・細胞検体の適切な取扱い. 日本病理学会 (編), ゲノム研究用・診療用病理組織検体取扱い規程. 羊土社, 130-137, 2019

 

3) 大喜多肇 : 腫瘍の鑑別に用いられる抗体 (各臓器別). 小児腫瘍. 北川昌伸, 他 (編), 免疫組織化学-実践的な診断・治療方針決定のために. 病理と臨 38 (臨時増刊号) : 284-290, 2020

 

P.105 掲載の参考文献

1) 日本病理学会 (編) : ゲノム研究用・診断用病理組織検体取扱い規程. 羊土社, 2019

 

2) 日本癌治療学会・日本病理学会 (編) : 領域横断的がん取扱い規約. 金原出版, 2019

 

Louis DN, et al. (eds) : WHO Classification of Tumours of the Central Nervous System : WHO Classification of Tumours, revised 4th ed., vol 1. IARC, 2016

 

Moch H, et al. (eds) : WHO Classification of Tumours of the Urinary System and Male Genital Organs : WHO Classification of Tumours, 4th ed., vol 8. IARC, 2016

 

Swerdlow SH, et al. (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues : WHO Classification of Tumours, revised 4th ed., vol 2. IARC, 2017

 

日本病理学会小児腫瘍組織分類委員会 (編) : 小児腫瘍組織カラーアトラス 第7巻 胚細胞腫瘍およびその他の臓器特異的希少腫瘍, 金原出版, 2017

 

WHO Classification of Tumours Editorial Board (ed) : Digestive System Tumours : WHO Classification of Tumours, 5th ed., vol 1. IARC, 2019

 

WHO Classification of Tumours Editorial Board (ed) : Soft Tissue and Bone Tumours : WHO Classification of Tumours, 5th ed., vol 3. IARC, 2020

 

WHO Classification of Tumours Editorial Board (ed) : Thoracic Tumours : WHO Classification of Tumours, 5th ed., vol 5. IARC, 2021

 

P.109 掲載の参考文献

1) Voss SD, et al. : The ALARA concept in pediatric oncology. Pediatr Radiol 39 : 1142-1146, 2009

PubMed

2) 日本放射線技術学会 : X線CT撮影における標準化～GALACTIC (改訂2版). 86-91, 2015

 

3) Swift CC, et al. : Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics 38 : 566-580, 2018

PubMed

4) Gottumukkala RV, et al. : Current and emerging roles of whole-body MRI in evaluation of pediatric cancer patients. Radiographics 39 : 516-534, 2019

PubMed

5) 日本小児科学会, 他. MRI検査時の鎮静に関する共同提言 (改訂版). 日本小児科学会雑誌 124 : 771-805, 2020

 

6) 小児核医学検査適正施行検討委員会 : 小児核医学検査適正施行のコンセンサスガイドライン 2020. 日本核医学会, 2020

 

7) Liu EK, et al. : Syndromic Wilms tumor : a review of predisposing condition, surveillance and treatment. Transl Androl Urol 9 : 2370-2381, 2020

PubMed

P.111 掲載の参考文献

1) Naito Y, et al. : Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26 : 233-283, 2021

PubMed

2) Kratz CP, et al. : Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 23 : e38-e45, 2017

PubMed

3) Allen CE, et al. : Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst 109 : djw274, 2017. doi : 10.1093/jnci/djw274.

 

P.117 掲載の参考文献

1) Skipper HE : Perspectives in cancer chemotherapy : Therapeutic design. Cancer Res 24 : 1295-1302, 1964

PubMed

2) Coldman AJ, et al : Role of mathematical modeling in protocol for mutation in cancer chemotherapy. Cancer Treat Rep 63 : 1041-1048, 1985

 

3) Moriyama T, et al : NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48 : 367-373, 2016

PubMed

4) Tomizawa D, et al : A risk-stratified therapy for infants with acute lymphoblastic leukemia : a report from the JPLSG MLL-10 trial. Blood 136 : 1813-1823, 2020

PubMed

5) Eisenhauer EA, et al : New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45 : 228-247, 2009

PubMed

6) 関水匡大, 他 : [1] 薬物治法. 1. 総論. 堀部敬三 (編), 小児がん診療ハンドブック. 医薬ジャーナル社, 124-133, 2011

 

P.123 掲載の参考文献

National Comprehensive Cancer Network : Antiemesis. IN : National Comprehensive Cancer Network Guideline. Version 2. 2017 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

 

Perry MC (ed.) : Perry's The Chemotherapy Source book. 5th ed., Lippincot Williams and Wilkins, 2012

 

P.129 掲載の参考文献

1) Dunsmore KP, et al. : Children's Oncology Group AALL0434 : A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 38 : 3282-3293, 2020

 

2) Hijiya N, et al. : Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118 : 6043-6049, 2011

 

3) Rubnitz JE, et al. : Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia : The AMl08 multicenter, randomized phase III trials. J Clin Oncol 37 : 2072-2081, 2019

 

4) Fleischhack G, et al. : IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation : experiences of a phase II trial. Br J Haematol 102 : 647-655, 1998

PubMed

5) Ishida H, et al. : Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. Pediatr Blood Cancer 62 : 883-889, 2015

PubMed

6) Barkaoui MA, et al. : Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment. Br J Haematol 191 : 825-834, 2020

PubMed

P.133 掲載の参考文献

1) Lassaletta A, et al. : Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma : A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol 34 : 3537-3543, 2016

PubMed

2) Minard-Colin V, et al. : Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumors : good tolerance profile and efficacy in rhabdomyosarcoma-a report from the Societe Francaise des Cancers et leucemies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer 48 : 2409-2416, 2012

 

3) Maki RG, et al. : Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 25 : 2755-2763, 2007

PubMed

4) Kolb EA, et al. : Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60 : 1325-1332, 2013

PubMed

5) London WB, et al. : Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma : a Children's Oncology Group study. J Clin Oncol 28 : 3808-3815, 2010

PubMed

6) Di Giannatale A, et al. : Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma : a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Eur J Cancer 50 : 170-177, 2014

PubMed

P.138 掲載の参考文献

1) JCCG長期フォローアップ委員会長期フォローアップガイドライン作成ワーキンググループ (編) : 小児がん治療後の長期フォローアップガイド. クリニコ出版, 2021

 

2) Chin M, et al. : Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan : Results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer 67 : e28194, 2020. doi : 10.1002/pbc.28194

 

3) Koh K, et al. : Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia : protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol 48 : 684-691, 2018

PubMed

4) Taga T, et al. : Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome : A Nationwide Prospective Study in Japan. Pediatr Blood Cancer 63 : 248-254, 2016

PubMed

5) Hasegawa D, et al. : Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors : A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer 67 : e28692, 2020

 

6) Breneman JC, et al. : Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21 : 78-84, 2003

 

7) Cushing B, et al. : Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors : a pediatric intergroup study-Pediatric Oncology Group 9094 and Children's Cancer Group 8882. J Clin Oncol 22 : 2691-2700, 2004

 

P.140 掲載の参考文献

Susan MB, et al. (eds.) : Principles and practice of pediatric oncology. 8th ed., Wolters Kluwer, 2021

 

日本小児がん学会 (編) : 小児がん診療ガイドライン 2016年版. 金原出版, 2016

 

七野浩之, 他 : 悪性新生物に用いられるくすり. 小児看護 19 : 1389-1395, 1996

 

P.146 掲載の参考文献

1) Porkka K, et al. : Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112 : 1005-1012, 2008

PubMed

2) Shen S, et al. : Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia : A Randomized Clinical Trial. JAMA Oncol 6 : 358-366, 2020

PubMed

3) Jabbour E, et al. : Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia : long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5 : e618-e627, 2018

PubMed

4) Sasaki K, et al. : Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : A propensity score analysis. Cancer 122 : 3650-3656, 2016

PubMed

5) Weiss AR, et al. : Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321) : a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 21 : 1110-1122, 2020

 

6) Albert CM, et al. : TRK Fusion Cancers in Children : A Clinical Review and Recommendations for Screening. J Clin Oncol 37 : 513-524, 2019

PubMed

7) Desai AV, et al. : Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. J Clin Oncol 38 ; 15_suppl 107 2020

 

8) Hong DS, et al. : Larotrectinib in patients with TRK fusion-positive solid tumours : a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21 : 531-540, 2020

PubMed

9) Krueger DA, et al. : Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363 : 1801-1811, 2010

PubMed

10) Franz DN, et al. : Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1) : a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381 : 125-132, 2013

PubMed

Fox E, et al. : Small-Molecule Pathway Inhibitors, General Principles of Chemotherapy. In : Blaney SM, et al. (eds), Pizzo & Poplack's Pediatric Oncology. 8th ed, Wolters Kluwer, 287-290, 2020

 

P.149 掲載の参考文献

1) Minard-Colin V, et al. : Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 382 : 2207-2219, 2020

PubMed

2) Yu AL, et al. : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363 : 1324-1334, 2010

PubMed

3) Jabbour E, et al. : The clinical development of antibody-drug conjugates-lessons from leukaemia. Nat Rev Clin Oncol 18 : 418-433, 2021

PubMed

4) Horibe K, et al. : A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Int J Hematol 112 : 223-233, 2020

PubMed

5) Dourthe ME, et al. : Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia doi : 10.1038/s41375-021-01281-7, 2021

 

P.154 掲載の参考文献

1) Stummer W, et al. : Extent of resection and survival in glioblastoma multiforme : identification of and adjustment for bias. Neurosurgery 62 : 564-576, 2008

PubMed

2) Barnholtz-Sloan JS, et al. : Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg 99 : 458-466, 2003

PubMed

3) Smoll NR : Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer 118 : 1313-1322, 2012

PubMed

4) Kanamori M, et al. : Optimal treatment strategy for intracranial germ cell tumors : a single institution analysis. J Neurosurg Pediatr 4 : 506-514, 2009

PubMed

5) Massimino M, et al. : Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol 18 : 1451-1460, 2016

PubMed

6) Report of Brain Tumor Registry of Japan (2005-2008). 14th edition. Neurol Med Chir (Tokyo) 57 (Suppl 1) : 9-102, 2017

 

7) Albright AL, et al. : Effects of medulloblastoma resections on outcome in children : a report from the Children's Cancer Group. Neurosurgery 38 : 265-271, 1996

 

8) Taylor MD, et al. : Molecular subgroups of medulloblastoma : the current consensus. Acta Neuropathol 123 : 465-472, 2012

PubMed

9) Thompson EM, et al. : Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup : a retrospective integrated clinical and molecular analysis. Lancet Oncol 17 : 484-495, 2016

PubMed

10) Thompson EM, et al. : The clinical importance of medulloblastoma extent of resection : a systematic review. J Neurooncol 139 : 523-539, 2018

PubMed

P.158 掲載の参考文献

1) 国定俊之, 他 : 切除縁評価法の問題点 : 悪性骨腫瘍. 日整会誌 88 : 588-594, 2014

Medical*Online

2) 日本整形外科学会骨・軟部腫瘍委員会 (編) : 整形外科・病理 悪性骨腫瘍取扱い規約. 第4版, 金原出版, 2015

 

3) 日本整形外科学会骨・軟部腫瘍委員会 (編) : 整形外科・病理 悪性軟部腫瘍取扱い規約. 第3版, 金原出版, 2002

 

4) Kawaguchi N, et al. : The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419 : 165-172, 2004

 

5) Kunisada T, et al. : Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors. Sci Rep 10 : 21578, 2020

PubMed

6) Fujiwara T, et al. : Mini-open excision of osteoid osteoma using intraoperative O-arm/Stealth navigation. J Orthop Sci 24 : 337-341, 2019

PubMed

7) Nakahara H, et al. : Minimally invasive plate osteosynthesis for osteofibrous dysplasia of the tibia : a case report. J Orthop Surg (Hong Kong) 18 : 374-377, 2010

PubMed

8) 日本整形外科学会骨軟部腫瘍委員会 : 腹腔外発生デスモイド型線維腫症診療ガイドライン 2019年版. 2019 (https://www.joa.or.jp/public/bone/)

 

9) Matsumoto S, et al. : "In situ preparation" : new surgical procedure indicated for soft-tissue sarcoma of a lower limb in close proximity to major neurovascular structures. Int J Clin Oncol 7 : 51-56, 2002

PubMed

10) 日本整形外科学会診療ガイドライン委員会/軟部腫瘍診療ガイドライン策定委員会編 : 軟部腫瘍診療ガイドライン 2020. 改訂第3版, 南江堂, 2020

 

11) Fujiwara T, et al. : Intraoperative O-arm-navigated resection in musculoskeletal tumors. J Orthop Sci 23 : 1045-1050, 2018

PubMed

P.162 掲載の参考文献

1) Monclair T, et al. : The International Neuroblastoma Risk Group (INRG) staging system : an INRG Task Force report. J Clin Oncol 27 : 298-303, 2009

PubMed

2) Brisse HJ, et al. : Guidelines for imaging and staging of neuroblastic tumors : consensus report from the International Neuroblastoma Risk Group Project. Radiology 261 : 243-257, 2011

PubMed

3) 米田光宏, 他 : 神経芽腫におけるIDRFの概念. 小児外科 42 : 627-632, 2010

Medical*Online

4) 田尻達郎, 他 : 神経芽腫低・中間リスク群に対する臨床研究におけるIDRFの評価と外科治療ガイドライン. 小児外科 43 : 1173-1178, 2011

Medical*Online

5) Hishiki T, et al. : Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07 : a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol 23 : 965-973, 2018

 

6) 越永従道 : 腎芽腫 (Wilms腫瘍). 小児内科 41 (suppl/小児疾患診療のための病態生理 2) : 1225-1230, 2009

 

7) 大植孝治, 他 : JCCG腎腫瘍委員会報告 : 両側Wilms腫瘍臨床研究RTBL14の結果-希少疾患に対する臨床試験施行上の問題点. 日小児血がん会誌 57 : 318-325, 2020

Medical*Online

8) Towbin AJ, et al. : 2017 PRETEXT : radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 48 : 536-554, 2018

PubMed

9) Hishiki T, et al. : Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2 : report from the JPLT. Pediatr Surg Int 27 : 1-8, 2011

 

P.164 掲載の参考文献

1) Packer RJ, et al. : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 : 4202-4208, 2006

PubMed

2) Michalski JM, et al. : Children's Oncology Group Phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 20 : 2685-2697, 2021

 

3) Evans AE, et al. : The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J neurosurg 72 : 572-582, 1990

PubMed

4) Aoyama H, et al. : Pathologically-proven intracranial germinoma treated with radiation therapy. Radiother Oncol 47 : 201-205, 1998

PubMed

5) Combs SE, et al. : Influence of radiotherapy treatment concept on the outcome of patients with localized ependymomas. Int J Radiat Oncol Biol Phys 71 : 972-978, 2008

PubMed

P.167 掲載の参考文献

1) Polishchuk AL, et al. : Likelihood of bone recurrence in prior sites of metastases in patients with high risk neuroblastoma. Int J Radiat Oncol Biol Phys 89 : 839-845, 2014

PubMed

2) Illidge T, et al : Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89 : 49-58, 2014

PubMed

3) Ishibashi N, et al. : National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan : survey of the Japanese Radiation Oncology Study Group (JROSG). J Radiat Res 59 : 477-483, 2018

 

P.174 掲載の参考文献

1) Ng LW, et al. : Dose sculpting intensity modulated radiation therapy for vertebral body sparing in children with neuroblastoma. Int J Radiat Oncol Biol Phys 101 : 550-557, 2018

PubMed

2) Baba K, et al. : An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer. Cancers (Basel) 13 : 349, 2021

PubMed

3) Mizumoto M, et al. : Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. Pediatr Blood Cancer 67 : e28617, 2020

PubMed

4) Oshiro Y, et al. : Spinal changes after craniospinal irradiation in pediatric patients. Pediatr Blood Cancer 67 : e28728, 2020

PubMed

5) Meadows AT, et al. : Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 2 : 1015-1018, 1981

PubMed

6) Merchant TE, et al. : Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 65 : 210-221, 2006

PubMed

7) Wallace WH, et al. : Ovarian failure following abdominal irradiation in childhood : natural history and prognosis. Clin Oncol (R Coll Radiol) 1 : 75-79, 1989

PubMed

8) Thomson AB, et al. : Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 16 : 311-334, 2002

PubMed

9) Indelicato DJ, et al. : Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy. Acta Oncol 53 : 1298-1304, 2014

PubMed

10) Gentile MS, et al. : Brainstem injury in pediatric patients with posterior fossa tumors treated with proton beam therapy and associated dosimetric factors. Int J Radiat Oncol Biol Phys 100 : 719-729, 2018

PubMed

11) Tucker MA, et al. : Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317 : 588-593, 1987

PubMed

12) de Vathaire F, et al. : Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 159 : 2713-2719, 1999

PubMed

13) Taddei PJ, et al. : Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol 54 : 2259-2275, 2009

PubMed

14) Sethi RV, et al. : Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 120 : 126-133, 2014

PubMed

P.178 掲載の参考文献

1) Majzner RG, et al. : Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 25 : 1341-1355, 2019

 

2) 今井千速 : CAR-T細胞療法の歴史と展望. 日小児血がん会誌 57 : 354-359, 2020

Medical*Online

3) Maude SL, et al. : Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med 378 : 439-448, 2018

 

4) Pasquini MC, et al. : Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4 : 5414-5424, 2020

PubMed

5) Lee DW, et al. : ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25 : 625-638, 2019

PubMed

P.184 掲載の参考文献

1) Kobolak J, et al. : Mesenchymal stem cells ; Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods 99 : 62-68, 2016

PubMed

2) 宮本憲一, 他 : 間葉系幹細胞の分類とその臨床応用. 再生医療, 16 : 204-209, 2017

Medical*Online

3) Burnham AJ, et al. : Mesenchymal stromal cells in hematopoietic cell transplantation. Blood Adv 4 : 5877-5887, 2020

PubMed

4) Fisher SA, et al. : Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev 1 : CD009768, 2019

 

5) Cheung TS, et al. : Mesenchymal Stromal Cells for Graft Versus Host Disease : Mechanism-Based Biomarkers. Front Immunol 11 : 1338, 2002

 

6) De Becker A, et al. : Mesenchymal Stromal Cell Therapy in Hematology : From Laboratory to Clinic and Back Again. Stem Cells Dev 24 : 1713-1729, 2015

 

P.187 掲載の参考文献

1) 厚生労働省健康局がん・疾病対策課 : 平成30年 全国がん登録 罹患数・率 報告. 2021 https://www.mhlw.go.jp/content/10900000/000794199.pdf

 

2) Katanoda K, et al. : Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J Clin Oncol 47 : 762-771, 2017

 

3) Trama A, et al. : Survival of European adolescents and young adults diagnosed with cancer in 2000-07 : population-based data from EUROCARE-5. Lancet Oncol 17 : 896-906, 2016

 

4) Ito Y, et al. : Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci 105 : 1480-1486, 2014

 

5) Unger JM, et al. : The Role of Clinical Trial Participation in Cancer Research : Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ Book 35 : 185-198, 2016

PubMed

P.190 掲載の参考文献

1) 清水千佳子, 他 : 厚生労働科学研究費補助金 (がん対策推進総合研究事業) 総合的な思春期・若年成人 (AYA) 世代のがん対策のあり方に関する研究. (研究代表者 : 堀部敬三) 平成28年度総括・分担研究報告書, 2017

 

2) がん診療連携拠点病院等の整備について. 厚生労働省健康局長通知 平成30年7月31日, 2019

 

3) 平成27～29年度厚生労働科学研究費補助金 (がん対策推進総合研究事業) 「総合的な思春期・若年成人 (AYA) 世代のがん対策のあり方に関する研究」班 (編) : 医療従事者が知っておきたいAYA世代がんサポートガイド. 金原出版, 2018

 

4) 日本癌治療学会 (編) : 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 金原出版, 2017

 

P.193 掲載の参考文献

1) Gatti RA, et al. : Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2 : 1366-1369, 1968

PubMed

2) 古庄巻史, 他 : 小児白血病治療における骨髄移植の試み. 小児科紀要 13 : 228-240, 1967

 

3) 松岡宏, 他 : HLA-partially mismatched MLC negative unrelated donorからの骨髄移植により, 免疫学的再建に成功した重症複合免疫不全の一例. 日医誌 88 ; 1898-1905, 1984

 

4) Gluckman E, et al. : Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321 : 1174-1178, 1989

 

5) 日本造血細胞移植データセンター (編) : 2020年度全国調査報告書別冊. 日本造血細胞移植データセンター, 2020 https://www.jdchct.or.jp/data/slide/2020/

 

P.196 掲載の参考文献

J. Apperley, et al. : EBMT-ESH Handbook on Haemapoietic Stem Cell Transplantation 6th ed, furum service editore, 490-611, 2012

 

日本造血・免疫細胞療法学会 (編) : 造血細胞移植ガイドライン. 小児急性骨髄性白血病 第3版, 2018年12月), 小児急性リンパ性白血病 第3版, 2018年9月, 悪性リンパ種 (小児) 第2版, 2019年5月, 小児固形腫瘍 第2版, 2019年5月, 再生不良性貧血, 2018年9月, 先天代謝異常症, 2019年5月, 原発性免疫不全症, 2018年2月, 遺伝性骨髄不全症候群, 2018年12月, 骨髄異形成症候群・骨髄増殖性腫瘍 (小児) 第3版, 2018年12月

 

厚生労働省先天代謝異常症に対する移植療法の確立とガイドラインの作成に関する研究班 (研究代表者 加藤俊一) : 先天代謝異常症に対する造血細胞移植ガイドライン. 厚生労働省, 2014

 

P.199 掲載の参考文献

1) Kanda J : Effect of HLA mismatch on acute graft-versus-host disease. Int J Hematol 98 : 300-308, 2013

PubMed

2) Yakoub-Agha I, et al. : Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy : a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24 : 5695-5702, 2006

PubMed

3) Shernan G, et al. : Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation. J Clin Oncol 39 : 373-385, 2021

 

4) Ikegame K, et al. : Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse : a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant 21 : 1495-1505, 2015

PubMed

5) Sano H, et al. : T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia. Int J Hematol 108 : 76-84, 2018

 

P.202 掲載の参考文献

1) Gyurkocza B, et al. : Conditioning regimens for hematopoietic cell transplantation : one size does not fit all. Blood 124 : 344-353, 2014

 

2) Bacigalupo A, et al. : Defining the intensity of conditioning regimens : working definitions. Biol Blood Marrow Transplant 15 : 1628-1633, 2009

PubMed

3) Cahu X, et al. : Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation : a report from the acute leukemia working party of EBMT. Bone Marrow Transplant 51 : 351-357, 2016

 

4) Nagler A, et al. : Allogeneic hematopoietic SCT for adults AML using i. v. BU in the conditioning regimen : outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone Marrow Transplant 49 : 628-633, 2014

 

5) Luznik L, et al. : HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14 : 641-650, 2008

PubMed

P.205 掲載の参考文献

1) 秋山秀樹, ほか : 採取担当医師の見地から. 骨髄採取マニュアルホームページ版 (2019.8.15 改訂). 日本骨髄バンク, 2015 https://www.jmdp.or.jp/documents/file/04_medical/f-up02-all-201908.pdf〔2021年9月アクセス〕

 

矢部普正 : 健常小児ドナーからの骨髄・末梢血幹細胞採取. 日本造血細胞移植学会ガイドライン委員会 (編). 造血細胞移植学会ガイドライン 第2巻. 医薬ジャーナル社, 110-126, 2015

 

Yabe M, et al. : Feasibility of marrow harvesting from pediatric sibling donors without hematopoietic growth factors and allotransfusion. Bone Marrow Transplant 49 : 921-926, 2014

PubMed

P.208 掲載の参考文献

1) 日本造血細胞移植学会 (編) : 造血細胞移植ガイドライン. GVHD (第4版). 造血細胞移植学会, 2018

 

Penack O, et al. : Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies : updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 7 : e157-e167, 2020

PubMed

Gonzalez RM, et al. : Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. Pharmacotherapy 40 : 756-772, 2020

PubMed

P.211 掲載の参考文献

1) Carreras E, et al. (eds.) : The EBMT Handbook : Hematopoietic Stem Cell Transplantation and Cellular Therapies. Springer, 2019

 

2) Olsson R, et al. : Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 48 : 537-543, 2013

PubMed

3) Takanashi M, et al. : The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 116 : 2839-2846, 2010

PubMed

4) Bacigalupo A, et al. : Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia : an EBMT analysis. Haematologica 100 : 696-702, 2015

PubMed

5) Kato M, et al. : Salvage allogeneic hematopoietic SCT for primary graft failure in children. Bone Marrow Transplant 48 : 1173-1178, 2013

PubMed

6) Schriber J, et al. : Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 16 : 1099-1106, 2010

PubMed

P.213 掲載の参考文献

1) Sarashina T, et al. : Risk factor analysis of bloodstream infection in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 35 : 76-80, 2013

PubMed

2) Kobayashi R, et al. : Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia. Biol Blood Marrow Transplant 20 : 1145-1149, 2014

PubMed

3) Fisher BT, et al. : Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation : a systematic review. J Pediatric Infect Dis Soc 7 : 191-198, 2018

PubMed

4) Kobayashi R, et al. : Lower gamma globulin level before conditioning is a risk factor for CMV antigenemia after pediatric allogeneic stem cell transplantation. Pediatric Blood & Cancer 66 : e27586, 2019

PubMed

5) Onozawa M, et al. : Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients : Hokkaido Hematology Study Group. Biol Blood Marrow Transplant 15 : 724-729, 2009

 

6) Ogata M, et al. : Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplanta transplantation : a multicenter, prospective study. Clin Infect Dis 57 : 671-681, 2013

 

7) Toriumi N, et al. : Risk factors for human herpesvirus 6 reactivation and its relationship with syndrome of inappropriate antidiuretic hormone secretion after stem cell transplantation in pediatric patients. J Pediatr Hematol Oncol 36 : 379-383, 2014

PubMed

P.217 掲載の参考文献

1) Carreras E, et al. : Noninfectious pulmonary complications. In : Carreras E, et al, (eds.), The EBMT Handbook : Hematopoietic Stem Cell Transplantation and Cellular Therapies. 393-401, 2019

 

2) Nakasone H, et al. : Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Bone Marrow Transplant 48 : 1317-1323, 2013

PubMed

3) Yakushijin K, et al. : Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation : Incidence, risk factors and outcomes. Bone Marrow Transplant 51 : 403-409, 2016

PubMed

4) 菊田敦 : 肝中心静脈閉塞症 (SOS/VOD) の治療. 日造血細胞移植会誌 10 : 36-47, 2021

Medical*Online

5) Dandoy CE, et al. : A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv 5 : 1-11, 2021.

PubMed

P.220 掲載の参考文献

1) Socie G, et al. : Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101 : 3373-3385, 2003

PubMed

2) 石田也寸志 : 小児造血幹細胞移植後の晩期合併症とQOL. 日造血細胞移植会誌 5 : 51-63, 2016

Medical*Online

3) 日本造血細胞移植学会ガイドライン委員会 (編) : 造血細胞移植学会ガイドライン 第4巻. 医薬ジャーナル社, 2017

 

4) Atsuta Y, et al. : Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol 25 : 435-441, 2014

PubMed

5) Majhail NS, et al. : 造血幹細胞移植後長期生存者に推奨されるスクリーニングおよび予防診療. 臨血 55 : 607-632, 2014

 

P.222 掲載の参考文献

1) Bingen, K., et al. : A multimethod assessment of psychosocial functioning and late effects in survivors of childhood cancer and hematopoietic cell transplant. J Pediatr Hematol Oncol 34 : 22-28, 2012

PubMed

2) Nakamura, Z. M., et al. : Psychiatric care in hematopoietic stem cell transplantation. Psychosomatics 60 : 227-237, 2019

PubMed

3) Packman, W., et al. : Psychological effects of hematopoietic SCT on pediatric patients, siblings and parents : a review. Bone Marrow Transplant 45 : 1134-1146, 2010

PubMed

4) Lazor, T., et al. : Instruments to measure anxiety in children, adolescents, and young adults with cancer : a systematic review. Support Care Cancer 25 : 2921-2931, 2017

 

5) Vrijmoet-Wiersma, C. M., et al. : Parental stress before, during, and after pediatric stem cell transplantation : a review article. Support Care Cancer 17 : 1435-1443, 2009

PubMed

6) Manne, S., et al. : Anxiety, depressive, and posttraumatic stress disorders among mothers of pediatric survivors of hematopoietic stem cell transplantation. Pediatrics 113 : 1700-1708, 2004

PubMed

7) Peikert, M. L, et al. : Psychosocial interventions for rehabilitation and reintegration into daily life of pediatric cancer survivors and their families : A systematic review. PLoS One 13 : e0196151, 2018

PubMed

8) Wiener, L. S., et al. : Hematopoietic stem cell donation in children : a review of the sibling donor experience. J Psychosoc Oncol 25 : 45-66, 2007

PubMed

9) MacLeod, K. D., et al. : Pediatric sibling donors of successful and unsuccessful hematopoietic stem cell transplants (HSCT) : a qualitative study of their psychosocial experience. J Pediatr Psychol 28 : 223-230, 2003

PubMed

10) Garcia, M. C., et al. : Motivations, experiences, and perspectives of bone marrow and peripheral blood stem cell donors : thematic synthesis of qualitative studies. Biol Blood Marrow Transplant 19 : 1046-1058, 2013

 

11) Kisch, A. M., et al. : The meaning of being a living kidney, liver, or stem cell donor-a meta-ethnography. Transplantation 102 : 744-756, 2018

PubMed

12) Bitan, M., et al. : Determination of eligibility in related pediatric hematopoietic cell donors : ethical and clinical considerations. recommendations from a working group of the worldwide network for blood and marrow transplantation association. Biol Blood Marrow Transplant 22 : 96-103, 2016

 

13) Pentz, R. D., et al. : Unmet needs of siblings of pediatric stem cell transplant recipients. Pediatrics 133 : e1156-62, 2014

PubMed

P.225 掲載の参考文献

1) Jain R, et al. : Superior mediastinal syndrome : emergency management. Indian J Pediatr 80 : 55-59, 2013

PubMed

2) Nossair F, et al. : Pediatric superior vena cava syndrome : An evidence-based systematic review of the literature. Pediatr Blood Cancer 65 : e27225, 2018

PubMed

3) Perger L, et al. : Management of children and adolescents with a critical airway due to compression by an anterior mediastinal mass. J Pediatr Surg 43 : 1990-1997, 2008

 

4) Takeda S, et al. : Surgical rescue for life-threatening hypoxemia caused by a mediastinal tumor. Ann Thorac Surg 68 : 2324-2326, 1999

PubMed

5) Anghelescu DL, et al. : Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses. Paediatr Anaesth 17 : 1090-1098, 2007

PubMed

6) Blank RS, et al. : Anesthetic management of patients with an anterior mediastinal mass : continuing professional development. Can J Anaesth 58 : 853-859, 860-867, 2011

 

7) Lillegard JB, et al. : Autologous blood patch for persistent air leak in children. J Pediatr Surg 48 : 1862-1866, 2013

 

P.228 掲載の参考文献

1) Kirkpatrick AW, et al. : Pediatric guidelines sub-committee for the world society of the abdominal compartment syndrome. Intensive Care Med 39 : 1190-1206, 2013

PubMed

2) Nickerson HJ, et al. : Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy : a Children's Cancer Group study. J Clin Oncol 18 : 477-486, 2000

 

3) Gupta H, et al. : Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg 42 : 998-1001, 2007

PubMed

4) Ahmed G, et al. : Surgery in perforated pediatric intestinal lymphoma. Eur J Surg Oncol 45 : 279-283, 2019

 

5) Roebuck DJ, et al. : External and internal-external biliary drainage in children with malignant obstructive jaundice. Pediatr Radiol 30 : 659-664, 2000

PubMed

6) Oparaji JA, et al. : Risk factors for asparaginase-associated pancreatitis : a systematic review. J Clin Gastroenterol 51 : 907-913, 2017

PubMed

7) 菊田敦 : 肝中心静脈閉塞症 (SOS/VOD) の治療. 日造血細胞移植会誌 10 : 36-47, 2021

Medical*Online

P.231 掲載の参考文献

Freedman JL, et al. : 38. Oncologic Emergencies. In : Pizzo PA, et al. (eds.), Principles and Practice of Pediatric Oncology. 7th ed., Lippincott Wiliams & Wilkins, 966-990, 2017

 

P.236 掲載の参考文献

1) Cairo MS, et al. : Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol 149 : 578-586, 2010

PubMed

2) 日本小児血液・がん学会 : 小児白血病・リンパ腫診療ガイドライン 2016年版. 金原出版, 2016

 

3) Howard SC, et al. : Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies : a systematic review. Ann Hematol 95 : 563-573, 2016

PubMed

4) Howard SC, et al. : Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies : a systematic review. Ann Hematol 95 : 563-573, 2016

PubMed

5) 日本臨床腫瘍学会 (編) : 腫瘍崩壊症候群 (TLS) 診療ガイダンス. 第2版, 金原出版, 2021

 

6) Kishimoto K, et al. : Febuxostat as a prophylaxis for tumor lysis syndrome in children with hematological malignancies. Anticancer Res 37 : 5845-5849, 2017

PubMed

7) Jones GL, et al. : Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169 : 661-671, 2015

 

8) 日本小児内分泌学会 : 抗利尿ホルモン (ADH) 不適合分泌症候群. 小児慢性特定疾病情報センターホームページ, 2014 https://www.shouman.jp/disease/details/05_07_010/ [2021年9月アクセス]

 

9) 日本小児内分泌学会 : 中枢性塩喪失症候群. 小児慢性特定疾病情報センターホームページ, 2014 https://www.shouman.jp/disease/details/05_09_014/ [2021年9月アクセス]

 

P.238 掲載の参考文献

1) Fisher MJ, et al. : Oncologic emergencies. In : Pizzo PA, et al. (eds.), Principles and Practice of Pediatric Oncology. 6th ed, Lippincott Williams & Wilkins, 1125-1151, 2011

 

2) Porcu P, et al. : Hyperleukocytic leukemias and leukostasis : a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 39 : 1-18, 2000

PubMed

3) Padmanabhan A, et al. : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis : the Eighth Special Issue. J Clin Apher 34 : 171-354, 2019

 

4) Ganzel C, et al. : Hyperleukocytosis, leukostasis and leukapheresis : practice management. Blood Rev 26 : 117-122, 2012

PubMed

5) Oberoi S, et al. : Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis : a systematic review and meta-analysis. Leukemia Res 38 : 460-468, 2014

 

6) Agrawal AK, et al. : Hematologic supportive care for children with cancer. In : Pizzo PA, et al. (eds.), Principles and Practice of Pediatric Oncology. 6th ed, LWW, 1125-1151, 2011

 

P.240 掲載の参考文献

Fisher MJ, et al. : Supportive Care of Children with Cancer Genitourinary Emergencies. In : Pizzo PA, et al. (eds.), Principles and Practice of Pediatric Oncology. 6th ed, LWW, 1134-1135, 2011

 

Seth R, et al. : Management of Common Oncologic Emergencies. Indian J Pediatr 78 : 709-717, 2011

PubMed

林富 : 小児固形腫瘍の外科的治療. 小児診療 67 : 551-557, 2004

Medical*Online

鎌田綾, 他 : oncologic emergency. [支持療法・長期フォローアップ] 小児診療 73 : 1395-1399, 2010

 

P.243 掲載の参考文献

1) Paw Cho Sing E, et al. : Classification of the acute emetogenicity of chemotherapy in pediatric patients : A clinical practice guideline. Pediatr Blood Cancer 66 : e27646, 2019

PubMed

2) Patel P, et al : Guideline for prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients : A focused update. Pediatr Blood Cancer 64 : e26542, 2017

 

3) Sherani F, et al : Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients. Curr Oncol Rep 21 : 89, 2019

PubMed

4) Urushiyama H, et al : Effect of Hangeshashin-To (Japanese Herbal Medicine Tj-14) on Tolerability of Irinotecan : Propensity Score and Instrumental Variable Analyses. J Clin Med 7 : 246, 2018

PubMed

P.246 掲載の参考文献

1) Rodgers C, et al : Growth patterns and gastrointestinal symptoms in pediatric patient safter hematopoietic stem cell transplantation. Oncol Nurs Forum 35 : 443-448, 2008

 

2) 曹英樹, 他 : 小児の造血幹細胞移植. 日本臨牀 68 : 574-577, 2010

Medical*Online

3) 「日本人の食事摂取基準 (2020年版) 」策定検討会 : 「日本人の食事摂取基準 (2020年版) 」策定検討会報告書. 厚生労働省, 2020

 

4) 日本静脈経腸栄養学会編 : 静脈経腸栄養ガイドライン. 第3版, 照林社, 2013

 

5) Bayram I, et al : The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatr Blood Cancer 52 : 571-574, 2009.

PubMed

P.249 掲載の参考文献

1) Ritwik P : Dental Care for Patients With Childhood Cancers. Ochsner J 18 : 351-357, 2018

PubMed

2) 山田慎一 : がん支持療法としての口腔機能管理の有効性. 信州医学雑誌, 67 : 279-288, 2019

Medical*Online

3) 仲江川雄太, 他 : 化学放射線療法による口内炎への内服・外用薬の使い方. MB ENTONI 231 : 109-113, 2019

Medical*Online

4) 春日井悠司 : 口腔粘膜・味覚障害. YORi-SOUがんナーシング, 10 : 112-117, 2020

Medical*Online

P.253 掲載の参考文献

Walker G, et al. : Capter 27. Central Venous Access. In : Carachi R, (eds.), The Surgery of Childhood Tumors. Springer, 587-596, 2008

 

土岐誠二, 他 : 静脈カテーテルの挿入, 留置法, アクセス管理. 静脈・経腸栄養 (第3版). 日本臨牀社, 152-159, 2010

 

土岐誠二 : 静脈栄養の多種投与経路. 日本静脈経腸栄養学会 (編), 日本静脈経腸栄養学会静脈経腸栄養ハンドブック. 南江堂, 246-262, 2011

 

井上善文 : 経腸栄養剤の種類と特徴. 日本静脈経腸栄養学会 (編), 日本静脈経腸栄養学会 静脈経腸栄養ハンドブック. 南江堂, 263-274, 2011

 

米国疾病対策センター (原著), 矢野邦夫 (監訳) : 留置カテーテル由来感染の予防のためのCDCガイドライン 2011. メディコン, 2011

 

Centers for Disease Control and Prevention (原著), 井上善文 (監訳) : CDCガイドライン 血管内留置カテーテル関連血流感染症予防対策ガイドライン 2011. ニプロ, 2011

 

P.256 掲載の参考文献

1) 日本小児血液・がん学会 (編) : 小児白血病・リンパ腫診療ガイドライン 2016年版, 金原出版, 2016

 

2) Pizzo PA : Infectious Complications in Pediatric Cancer Patients. In : Pizzo PA et al. (eds), Principles and Practice of Pediatric Oncology. 5th ed., Lippincott Williams & Wilkins, 1269, 2006

 

3) Freifeld AG, et al. : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 : e56-e93, 2011

 

4) Engels EA, et al. : Efficacy of quinolone prophylaxis in neutropenic cancer patients : a meta-analysis. J Clin Oncol 16 : 1179-1187, 1998

PubMed

5) Yeh TC, et al. : Severe infection in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer 120 : 1255-1262, 2014

PubMed

6) Alexander S, et al. : Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation : A Randomized Clinical Trial. JAMA 320 : 995-1004, 2018

 

7) Groll AH, et al. : Fourth European Conference on Infections in Leukaemia (ECIL-4) : guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15 : e327-e340, 2014

PubMed

8) Sung L, et al. : Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer : a meta-analysis of randomized controlled trials. J Clin Oncol 22 : 3350-3356, 2004

 

9) Relling MV, et al. : Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101 : 3862-3867, 2003

PubMed

10) Ehlers S, et al. : Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 28 : 2591-2597, 2010

PubMed

P.258 掲載の参考文献

1) 福島啓太郎 : 発熱性好中球減少症の標準的治療は何か. 日本小児血液・がん学会 (編), 小児白血病・リンパ腫診療ガイドライン 2016年版. 金原出版, 133-138, 2016

 

2) Freifeld AG, et al. : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52 : e56-e93, 2011

 

3) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン～がん薬物療法時の感染対策～. 改訂第2版, 南江堂, 2017

 

4) Lehrnbecher T, et al. : Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients : 2017 Update. J Clin Oncol 35 : 2082-2094, 2017

PubMed

5) 福島啓太郎, 他 : 小児領域. 真菌症フォーラム深在性真菌症のガイドライン作成委員会 (編), 深在性真菌症の診断・治療ガイドライン 2014 小児領域改訂版. 協和企画, 2016

 

P.261 掲載の参考文献

1) 日本小児血液・がん学会 (編) : 小児白血病・リンパ腫診療ガイドライン 2016年版. 金原出版, 139-146, 2016

 

2) 福島啓太郎, 他 : 小児領域. 真菌症フォーラム. 深在性真菌症のガイドライン作成委員会 (編), 深在性真菌症の診断・治療ガイドライン 2014 小児領域改訂版. 協和企画, 182-197, 2016

 

3) 森有紀, 他 : 真菌感染症の予防と治療 (第2版). 日本造血・免疫細胞療法学会 (編), 造血細胞移植ガイドライン. 2021 https://www.jshct.com/uploads/files/guideline/01_04_shinkin02.pdf [2022年2月アクセス]

 

4) Donnelly JP, et al : Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71 : 1367-1376, 2020

 

5) 福島啓太郎 : 小児における薬物動態と投与設計. 日本医真菌学会 (編), 侵襲性カンジダ症に対するマネジメントのための臨床実践ガイドライン. 日本医真菌学会, 100-104, 2021

 

6) Pappas PG, et al. : Clinical practice guideline for the management of candidiasis : 2016 update by the Infectious Disease Society of America. Clin Infect Dis 62 : e1-50, 2016

 

7) Groll AH, et al. : Fourth European Conference on Infections in Leukaemia (ECIL-4) : guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15 : e327-340, 2014

PubMed

P.263 掲載の参考文献

1) Ferrari A, et al. : Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia : case report and review of literature. Leukemia 19 : 2019-2021, 2005

 

2) Styczynski J, et al. : Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT : guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43 : 757-770, 2009

PubMed

3) Hill G, et al. : Recent steroid therapy increases severity of varicella infection in children with acute lymphoblastic leukemia. Pediatrics 116 : e525-e529, 2005

PubMed

4) Sehulster L, et al. : Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52 (RR-10) : 1-42, 2003

 

5) 日本造血細胞移植学会 : 造血細胞移植ガイドライン サイトメガロウイルス感染症. 第4版, 2018 https://www.jshct.com/uploads/files/guideline/01_03_01_cmv04.pdf

 

6) Ljungman P, et al. : Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42 : 227-240, 2008

PubMed

7) Engelhard D, et al. : European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients : summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15 : 219-232, 2013

 

8) Khanna N, et al. : Respiratory syncytial virus infection in patients with hematological diseases : single-center study and review of the literature. Clin Infect Dis 46 : 402-412, 2008

PubMed

9) Hirsch HH, et al. : Fourth European Conference on Infections in Leukaemia (ECIL-4) : guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 56 : 258-266, 2013

PubMed

P.265 掲載の参考文献

1) 日本小児感染症学会 (監修), 「小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014」作成委員会 : 小児の臓器移植および免疫不全状態における予防接種ガイドライン 2014. 協和企画, 2014

 

2) Ruggiero A, et al : How to manage vaccinations in children with cancer. Pediatr Blood Cancer 57 : 1104-1108, 2011

PubMed

3) Velardi E, et al : T cell regeneration after immunological injury. Nat Rev Immunol 21 : 277-291, 2021

PubMed

4) 日本造血細胞移植学会 : 造血細胞移植ガイドライン 予防接種. 第3版, 2018 https://www.jshct.com/uploads/files/guideline/01_05_vaccination_ver03.pdf

 

P.268 掲載の参考文献

厚生労働省医薬・生活衛生局 : 血液製剤の使用指針 (平成31年3月). 2019

 

厚生労働省医薬・生活衛生局 : 輸血療法の実施に関する指針 (平成17年9月 [令和2年3月一部改正]). 2020

 

日本赤十字社 : 輸血情報 (日本赤十字社ホームページ). https://www.jrc.or.jp/mr/news/transfusion/

 

日本輸血・細胞治療学会 : 指針/ガイドライン (日本輸血・細胞治療学会ホームページ). http://yuketsu.jstmct.or.jp/medical/guidelines/

 

大戸斉, 他 (編) : 小児輸血学. 中外医学社, 2006

 

P.271 掲載の参考文献

1) 厚生労働省医薬・生活衛生局 : 血液製剤の使用指針 (平成31年3月). 2019 https://www.mhlw.go.jp/content/11127000/000493546.pdf [2021年9月アクセス]

 

2) Mitchell L, et al. : Increased endogenous thrombin generation in children with acute lymphoblastic leukemia : risk of thrombotic complications in L-Asparaginase induced antithrombin III deficiency. Blood 83 : 386-391, 1994

 

3) Bercovitz RS, et al. : Thrombocytopenia and bleeding in pediatric oncology patients. Hematology Am Soc Hematol Educ Program 2012 : 499-505, 2012

PubMed

4) British Committee for standards in Haematology, Blood Transfusion TaskForce : Guidelines for the use of platelet transfusions. Br J Haematol 122 : 10-23, 2003

 

5) 宗教的輸血拒否に関する合同委員会 : 宗教的輸血拒否に関するガイドライン. 2008 https://anesth.or.jp/files/pdf/guideline.pdf [2021年9月アクセス]

 

P.274 掲載の参考文献

1) 岡崎仁, 他 : 科学的根拠に基づいた輸血有害事象対応ガイドライン. Japanese J Transfus Cell Ther 65 : 1-9, 2019

 

2) Ikebe E, et al. : Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study. Transfus Apher Sci 58 : 162-168, 2019

PubMed

3) Vlaar APJ, et al. : A consensus redefinition of transfusion-related acute lung injury. Transfusion 59 : 2465-2476, 2019

PubMed

4) Hod EA, et al. : Noninfectious complications of blood transfusion. In : Cohn CS, et al. (eds), Technical Manual. 20th ed, AABB, Bethesda, 643-645, 2020

 

5) International Society of Blood Transfusion Working Party on Haemovigilance in collaboration with the International Haemovigilance Network and AABB : Transfusion-associated circulatory overload (TACO) Definition (2018) https://www.isbtweb.org/fileadmin/user_upload/TACO_2018_definition_March_2019.pdf

 

6) Semple JW, et al. : Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood 133 : 1840-1853, 2019

PubMed

7) Uchida S, et al. : Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood. Transfus Med 23 : 416-422, 2013

PubMed

8) Shander A, et al : Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 50 : 1144-1155, 2010

PubMed

9) Kleinman SH, et al. : Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 49 : 2454-2489, 2009

PubMed

P.278 掲載の参考文献

1) Armstrong GT, et al. : Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 374 : 833-842, 2016

PubMed

2) Suh E, et al. : Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers : a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol 21 : 421-435, 2020

 

3) Armstrong GT, et al. : Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32 : 1218-1227, 2014

PubMed

4) Bhakta N, et al. : The cumulative burden of surviving childhood cancer : an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 390 : 2569-2582, 2017

PubMed

5) American Academy of Pediatrics Section on Hematology/Oncology, Children's Oncology Group : Long-term follow-up care for pediatric cancer survivors. Pediatrics 123 : 906-915, 2009

 

6) JCCG長期フォローアップ委員会長期フォローアップガイドライン作成ワーキンググループ (編) : 小児がん治療後の長期フォローアップガイド. クリニコ出版, 2021

 

7) White PH, et al. : Supporting the Health Care Transition From Adolescence to Adulthood in the Medical Home. Pediatrics 142 : e20182587, 2018

PubMed

P.281 掲載の参考文献

1) Cheung YT, et al. : chronic health conditions and neurocognitive function in aging survivors of childhood cancer : a report from the childhood cancer survivor study. J Natl Cancer Inst 110 : 411-419, 2018

PubMed

2) Peng L, et al. : Neurocognitive impairment in Asian childhood cancer survivors : a systematic review. Cancer Metastasis Rev 39 : 27-41, 2020

PubMed

3) 日本医療研究開発機構研究費「革新的がん医療実用化研究事業」「小児脳腫瘍に対する多施設共同研究による治療開発」日本小児がんグループ脳腫瘍委員会神経心理評価小委員会 (編) : 小児脳腫瘍治療後の神経心理学的合併症についての手引き 第1.1版. 2018

 

4) Jacola LM, et al. : Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia : a report from the Childhood Cancer Survivor Study. Lancet Psychiatr 3 : 965-972, 2016

 

5) Wurz A, et al. : A proof-of-concept sub-study exploring teasibility and preliminary evidence for the role of physical activity on neural activity during executive functioning tasks among young adults after cancer treatment. BMC Neurol 21 : 300, 2021

 

P.283 掲載の参考文献

1) Gebauer J, et al. : Long-Term Endocrine and metabolic consequences of cancer treatment : A systematic review. Endocr Rev 40 : 711-767, 2019

PubMed

2) Shalet SM, et al. : Growth and pituitary function in children treated for brain tumours or acute lymphoblastic leukaemia. Horm Res 30 : 53-61, 1988

 

3) 日本小児内分泌学会 (編) : 小児がんの内分泌診療の手引き. 診断と治療社, 2021

 

P.285 掲載の参考文献

1) Feijen EAM, et al. : Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late- Onset Cardiotoxicity. JAMA Oncol 5 : 864-871, 2019

PubMed

2) von Hoff DD, et al. : Risk factor for doxorubicin-induced congestive heart failure. Ann Intern Med 91 : 710-717, 1979

PubMed

3) Steinherz LJ, et al. : Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 : 1672-1677, 1991

PubMed

4) Blanco JG, et al. : Anthracycline-related cardiomypathy after childhood cancer : role of polymophisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol 30 : 1415-1421, 2012

 

5) Tukenova M, et al. : Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28 : 1308-1315, 2010

 

6) Bate JE, et al. : Therapy-Related Cardiac Risk in Childhood Cancer Survivors : An analysis of the Childhood Cancer Survivor Study. J Clin Oncol 37 : 1090-1101, 2019

 

7) The Children's Oncology Group (eds.) : Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 5.0-October 2018

 

8) Armenian SH, et al. : Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16 : e133-e136, 2015

 

9) Mertens AC, et al. : Cause-specific late mortality among 5-year survivors of childhood cancer : the childhood Cancer Survivor Study. J Natl Cancer Inst 100 : 1368-1379, 2008

PubMed

10) Menna P, et al. : Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21 : 978-989, 2008

PubMed

11) Cardinale D, et al. : Anthracycline-induced cardiomyopathy : clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55 : 213-220, 2010

PubMed

12) Ewer MS, et al. : Cardiac Complications. In : Holland JF, et al. (eds.), Cancer Medicine. 3rd ed, Lippincott Williams & Wilkins, 3197-3215, 1997

 

13) Mathe G, et al. : An oriented phase II trial of THP-adriamycin in breast carcinoma. Biomed Pharmacother 40 : 376-379, 1986

PubMed

P.288 掲載の参考文献

1) Armstrong G T, et al. : Late mortality among 5-year survivors of childhood cancer : A summary from the Childhood Cancer Survivor Study. J Clin Oncol 27 : 2328-2338, 2009

PubMed

2) Venkatramani, R, et al. : Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. Int J Radiat Oncol Biol Phys 86 : 942-948, 2013

PubMed

3) Evans AE, et al. : Late effects of treatment for Wilms' tumor. a report from the National Wilms' Tumor Study Group. Cancer 67 : 331-336, 1991

 

4) Jenney ME : Malignant Disease and the Lung. Paediatr. Respir. Rev 1 : 279-286, 2000

PubMed

5) Goldiner P L, et al. : Factors Influencing Postoperative Morbidity and Mortality in Patients Treated with Bleomycin. Br Med J 1 : 1664-1667, 1978

PubMed

6) Aakre BM, et al. : Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc 89, 181-189, 2014

PubMed

7) Frisk P, et al. : Pulmonary function after autologous bone marrow transplantation in children : A Long-Term Prospective Study. Bone Marrow Transplant 33 : 645-650, 2004

PubMed

8) Denbo JW, et al. : Long-term pulmonary function after metastasectomy for childhood osteosarcoma : A report from the St Jude Lifetime Cohort Study. J Am Coll Surg 219 : 265-271, 2014

PubMed

P.290 掲載の参考文献

1) Kooijmans EC, et al. : Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 3 : CD008944, 2019

PubMed

2) Jones DP, et al. : Renal late effects in patients treated for cancer in childhood : a report from the Children's Oncology Group. Pediatr Blood Cancer 51 : 724-731, 2008

 

3) Dekkers IA, et al. : Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol 8 : 922-929, 2013

PubMed

4) Ehrhardt MJ, et al. : Renal and Hepatic Health After Childhood Cancer. Pediatr Clin North Am 67 : 1203-1217, 2020

PubMed

5) Children's Oncology Group : Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 5.0, Children's Oncology Group, 2018

 

6) Frangoul H, et al. : Long-term follow-up and management guidelines in pediatric patients after allogeneic hematopoietic stem cell transplantation. Semin Hematol 49 : 94-103, 2012

PubMed

7) Breslow NE, et al. : End stage renal disease in patients with Wilms tumor : results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 174 : 1972-1975, 2005

 

8) Ritchey M, et al. : Late effects on the urinary bladder in patients treated for cancer in childhood : a report from the Children's Oncology Group. Pediatr Blood Cancer 52 : 439-446, 2009

 

P.292 掲載の参考文献

1) Goldsby R, et al. : Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology 140 : 1464-1471, 2011

PubMed

2) Children's Oncology Group : Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 5.0, October 2018

 

3) Madenci AL, et al. : Late-onset anorectal disease and psychosocial impact in survivors of childhood cancer : a report from the Childhood Cancer Survivor Study. Cancer 125 : 3873-3881, 2019

PubMed

4) Castellino S, et al. : Hepato-biliary late effects in survivors of childhood and adolescent cancer : a report from the Children's Oncology Group. Pediatr Blood Cancer 54 : 663-669, 2010

 

5) Renee LM, et al. : Surveillance of hepatic late adverse effects in a large cohort of long-term survivors of childhood cancer : Prevalence and risk factors. European Journal of Cancer 49 : 185-193, 2013

 

6) Nada AY, et al. : Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr 16 : 207-218, 2013

 

P.295 掲載の参考文献

1) Van den Brink M, et al. : Smell and taste function in childhood cancer patients : a feasibility stury. Support Care Cancer 29 : 1619-1628, 2021

 

2) Cohen J, et al. : Taste and smell function in pediatric blood and marrow transplant patients. Appetite 75 : 135-140, 2014

 

3) Knight KRG, et al. : Ototoxicity in children receiving platinum chemotherapy : underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23 : 8588-8596, 2005

PubMed

4) Clemens E, et al. : Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 20 : e29-e41, 2019

 

5) Whelan KF, et al. : Ocular Late Effects in Childhood and Adolescent Cancer Survivors : A Report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 54 : 103-109, 2010

PubMed

P.296 掲載の参考文献

1) Seremidi K, et al. : Late effects of chemo and raditaion treatment on dental structures of childhood cancer survivors. A systematic review and mata-analyses. Head and Neck 41 : 3422-3433, 2019

 

2) 河上智美 : 歯科における小児がん治療後の留意点とフォローアップ. 日小児血がん会誌 50 : 378-382, 2013

Medical*Online

3) 三穂蓉子 : 小児白血病治療後に認められた歯の形成障害について 第2報 : 移植前処置 (ブスルファン投与および全身放射線照射の影響) による比較. 障害者歯 25 : 93-99, 2004

 

4) 前田美穂, 他 : 5 口腔, 歯. JCCG 長期フォローアップ委員会 (編) : 小児がん治療後の長期フォローアップガイド 臓器別・症状別ガイド. クリニコ出版, 49-53, 2021

 

5) 日本小児歯科学会 : 日本人小児における乳歯・永久歯の萌出時期に関する調査研究 II その1. 乳歯について. 小児歯誌 57 : 45-53, 2019

Medical*Online

6) 日本小児歯科学会 : 日本人小児における乳歯・永久歯の萌出時期に関する調査研究 II その2. 永久歯について. 小児歯誌 57 : 363-373, 2019

Medical*Online

P.298 掲載の参考文献

1) Schriock EA, et al. : Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 9 : 400-405, 1991

PubMed

2) Gawade PL, et al. : A systematic review of selected musculoskeletal late effects in survivors of childhood cancer. Curr Pediatr Rev 10 : 249-262, 2014

PubMed

3) Fragu P, et al. : Long-term effects in skin and thyroid after radiotherapy for skin angiomas : a French retrospective cohort study. Eur J Cancer 27 : 1215-1222, 1991

PubMed

4) Teepen JC, et al. : Long-term risk of skin cancer among childhood cancer survivors : a DCOG-LATER Cohort Study. J Natl Cancer Inst 111 : 845-853, 2019

PubMed

5) Sakamoto K, et al. : Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. J Clin Oncol 36 : 900-907, 2018

 

6) Shima H, et al. : Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 159 : 676-681, 2011

PubMed

P.300 掲載の参考文献

1) Chemaitilly W, et al. : Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy : a report from the St Jude Lifetime Cohort Study. J Clin Oncol 33 : 492-500, 2015

PubMed

2) Assouline E, et al. : Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility. Clin Lymphoma Myeloma Leuk 13 : 704-710, 2013

PubMed

3) Signorello LB, et al. : Female survivors of childhood cancer : preterm birth and low birth weight among their children. J Natl Cancer Inst 98 : 1453-1461, 2006

 

4) Signorello LB, et al. : Stillbirth and neonatal death in relation to radiation exposure before conception : a retrospective cohort study. Lancet 376 : 624-630, 2010

 

P.304 掲載の参考文献

1) Armstrong GT, et al. : Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32 : 1218-1227, 2014

PubMed

2) Reulen RC, et al. : Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 305 : 2311-2319, 2011

PubMed

3) Olsen JH, et al. : Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 101 : 806-813, 2009

PubMed

4) Cardous-Ubbink MC, et al. : Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer 43 : 351-362, 2007

PubMed

5) Ishida Y, et al. : Secondary cancers among children with acute lymphoblastic leukaemia treated by the Tokyo Children's Cancer Study Group protocols : a retrospective cohort study. Br J Haematol 164 : 101-112, 2014

 

6) Ishida Y, et al. : Secondary cancers after a childhood cancer diagnosis : a nationwide hospital-based retrospective cohort study in Japan. Int J Clin Oncol 21 : 506-516, 2016

PubMed

7) Guerin S, et al. : Treatment-adjusted predisposition to second malignant neoplasms after a solid cancer in childhood : a case-control study. J Clin Oncol 25 : 2833-2839, 2007

PubMed

P.308 掲載の参考文献

1) Goldman A, et al. (eds.) : Oxford Textbook of Palliative Care for Children 2nd Edition. Oxford University Press, 2012

 

Jassal SS, et al. (eds.) : Basic Symptom Control in Paediatric Palliative Care : The Rainbows Children's Hospice Guidelines 7th Edition, 2008

 

日本緩和医療学会緩和医療ガイドライン作成委員会 (編) : がん疼痛の薬物療法に関するガイドライン 2020年版. 金原出版, 2020

 

P.311 掲載の参考文献

1) Goldman A, et al. : Symptoms in children/young people with progressive malignant disease : United Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses Forum Survey. Pediatrics 117 : e1179-1186, 2006

 

2) Morita T, et al. : A prospective study on the dying process in terminally ill cancer patients. Am J Hosp Palliat Care 15 : 217-222, 1998

 

3) Karnik NS, et al. : Subtypes of pediatric delirium : a treatment algorithm. Psychosomatics 48 : 253-257, 2007

PubMed

4) 日本緩和医療学会緩和医療ガイドライン作成委員会 (編) : 苦痛緩和のための鎮静に関するガイドライン 2010年版. 金原出版, 2010

 

5) Royal College of Paediatrics and Child Health (ed.) : Withholding or Withdrawing Life Saving Medical Treatment in Children : A framework for Practice. 2nd ed., Royal College of Paediatrics and Child Health, 2004

 

6) Sprung CL, et al. : End-of-life practices in European intensive care units : The Ethicus Study. JAMA 290 : 790-797, 2003

PubMed

7) 厚生労働省 : 終末期医療の決定プロセスに関するガイドライン 平成19年5月. 厚生労働省, 2007

 

8) 日本学術会議・臨床医学委員会終末期医療分科会 : 対外報告終末期医療のあり方について-亜急性型の終末期について-. 日本学術会議, 2008

 

9) 日本集中治療医学会, 他 : 救急・集中治療における終末期医療に関するガイドライン～3 学会からの提言～. 日本集中治療医学会, 日本救急医学会, 日本循環器学会, 2014

 

10) 日本老人医学会 : 高齢者ケアの意思決定プロセスに関するガイドライン-人工的水分・栄養補給の導入を中心として. 日本老人医学会, 2012

 

P.314 掲載の参考文献

1) Ito Y, et al. : Good death for children with cancer : a qualitative study. Jpn J Clin Oncol 45 : 349-355, 2015

 

2) Yoshida S, et al. : Japanese physicians' attitudes toward end-of-life discussion with pediatric patients with cancer. Support Care Cancer, 26 : 3861-3871, 2018

PubMed

3) 藤井裕治, 他 : 終末期の小児がんの子どもたちに認められた死の予感と不安. 日小児会誌 106 : 394-400, 2002

 

4) Yoshida S, et al. : A comprehensive study of the distressing experiences and support needs of parents of children with intractable cancer. Jpn J Clin Oncol 44 : 1181-1188, 2014

PubMed

5) Yoshida S, et al. : Barriers of healthcare providers against end-of-life discussions with pediatric cancer patients. Jpn J Clin Oncol 44 : 729-735, 2014

PubMed

P.316 掲載の参考文献

1) 平成30年度厚生労働省委託事業 平成30年度小児在宅医療に関する人材養成講習会テキスト, 国立研究開発法人国立成育医療研究センター, 2018

 

2) Fujii Y, et al. : Analysis of the circumstances at the end of life in children with cancer : a single institution's experience in Japan. Pediatr Int 45 : 54-59, 2003

 

3) 金井理恵, 他 : チームとしての小児在宅ターミナルケア. 日小児血液会誌 19 : 123-130, 2005

 

4) 押川真喜子 : 小児がん患者の終末期在宅ケアの支援の在り方についての研究. 平成22年度厚生労働科学研究費補助金 (がん臨床研究事業) 総括・分担研究報告書. 厚生労働省, 2012

 

5) 朴明子 : アンケート調査に基づく群馬県内の小児在宅緩和ケアの可能性について. 日小児血がん会誌 51 : 3-8, 2014

Medical*Online

6) 冨田直 : 小児在宅医療における病院と地域との連携. 在宅新療 0-100 4 : 326-332, 2019

 

7) 上田悟史, 他 : 終末期在宅緩和ケア後, 自宅で看取りを行った再発難治性胸膜肺芽腫の1例. 日小児血がん会誌 56 : 40-45, 2019

Medical*Online

P.319 掲載の参考文献

1) Hendrickson KC : Morbidity, mortality, and parental grief : a review of the literature on the relationship between the death of a child and the subsequent health of parents. Palliat Support Care 7 : 109-119, 2009

PubMed

2) Li J, et al. : Hospitalization for mental illness among parents after the death of a child. N Engl J Med 352 : 1190-1196, 2005

 

3) McCarthy MC, et al. : Prevalence and predictors of parental grief and depression after the death of a child from cancer. J Palliat Med 13 : 1321-1326, 2010

 

4) Rosenberg AR, et al. : Systematic review of psychosocial morbidities among parents of children with cancer. Pediatr Blood Cancer 58 : 503-512, 2012

PubMed

5) Wiener L et al. : Family bereavement care after the death of a child. In : Kissane DW, et al. (eds.), Bereavement Care for Families. Routledge, 2014

 

6) Tedeschi RG et al. : Helping Bereaved Parents : A Clinician's Guide. Routledge, 2004

 

7) Johnston EE, et al. : Bereaved parents' views on end-of-life care for children with cancer : Quality marker implications. Cancer 126 : 3352-3359, 2020

PubMed

8) Helton G, et al. : Parental Perceptions of Hospital-Based Bereavement Support Following a Child's Death From Cancer : Room for Improvement. J Pain Symptom Manage 61 : 1254-1260, 2021

 

9) Pohlkamp L, et al. : Parents' views on what facilitated or complicated their grief after losing a child to cancer. Palliat Support Care 26 : 1-6, 2020

PubMed

10) American Academy of Pediatrics : Supporting the family after the death of a child. Pediatrics 130 : 1164-1169, 2012

 

11) Kochen EM, et al. : When a child dies : a systematic review of well-defined parent-focused bereavement interventions and their alignment with grief- and loss theories. BMC Palliat Care 19 : 28, 2020

 

P.322 掲載の参考文献

1) 細谷亮太 : 小児がん患者における終末期ケア・看取りの医療の実際. 船戸正久 (編), 新生児・小児医療にかかわる人のための看取りの医療. 診断と治療社, 44-52, 2010

 

2) 細谷亮太, 他 : チーム医療とトータル・ケア. 細谷亮太, 他 (著), 小児がん-チーム医療とトータル・ケア. 中央公論新社, 175-182, 2008

 

3) 西村昴三 : 小児がんの包括医療 (1) 総論. 赤塚順一, 他 (編), 小児がん. 医薬ジャーナル社, 351-355, 2000

 

4) The American Academy of Pediatrics [Committee on Hospital Care and Institute for Patient- and Family-Centered Care] : Patient- and family-centered care and the pediatrician's role. Pediatrics 129 : 394-404, 2012

 

5) 大坂巌 : 緩和医療におけるチーム医療. 癌と化療, 40 : 444-447, 2013

Medical*Online

P.324 掲載の参考文献

1) 文部科学省, 厚生労働省, 経済産業省 : 人を対象とする生命科学・医学系研究に関する倫理指針 (令和3年3月23日). 文部科学省, 厚生労働省, 経済産業省, 2021

 

2) Pizzo PA, et al. (eds.) : Principles and Practice of Pediatric Oncology. 7 th ed, Lippincott Williams & Wilkins, 2016

 

3) Kliegman RM, et al. (eds.) : Nelson Textbook of Pediatrics. 21st ed, Elsevier, 2019

 

4) Children's Assent. (National Cancer Instituteのホームページ内), Health Professional Version, Updated : March 11, 2020 https://www.cancer.gov/about-cancer/treatment/clinical-trials/patient-safety/childrens-assent

 

5)世界医師会 (WMA) : ヘルシンキ宣言. (採択) 1964, (最新改訂) 2013 https://www.med.or.jp/doctor/international/wma/helsinki.html

 

P.327 掲載の参考文献

1) 駒松仁子 : 子ども理解を深める. 谷川弘治, 他 (編), 病気の子どもの心理社会的支援入門. 第2版, ナカニシヤ出版, 19-47, 2009

 

2) 大園秀一 : 小児がん. 内富庸介, 他 (編), 精神腫瘍学. 医学書院, 296-308, 2011

 

3) Rourke MT, et al. : 心理社会的側面. Schwartz CL, 他 (編), 日本小児白血病リンパ腫研究グループ長期フォローアップ委員会 (監訳), 小児がん経験者の長期フォローアップ : 集学的アプローチ. 日本医学館, 274-282, 2008

 

4) Stuber ML : Psychiatric Impact of Childhood Cancer. In : Shulamith K, et al. (eds.), Pediatric Psycho-oncology : Psychosocial Aspects and Clinical Interventions. 2nd ed, Wiley-Blackwell, 43-51, 2012

 

P.329 掲載の参考文献

1) 武田鉄郎 : 小児慢性疾患患者に対する教育支援の実際. 小児看護 33 : 1198-1201, 2010

 

2) 平賀健太郎 : 小児がん患児の前籍校への復学に関する現状と課題-保護者への質問紙調査の結果より. 小児保健研 66 : 456-464, 2007

Medical*Online

3) 永吉美智枝, 他 : 小児がん経験者の入院前から復学後における地元の友達との繋がり-友達との繋がりを維持する要因. 育療 68 : 1-9, 2021

 

4) 平賀健太郎 : 小児慢性疾患患者に対する復学支援. 小児看護 33 : 1209-1214, 2010

 

5) 濱中喜代, 他 (編著) : 多職種合同ワークショップ「病気の子どものトータルケアセミナー」研修プログラム集, 第9集 小児医療の現場で多職種が連携・協働していく為に求められること. 2018年3月 https://0d2846ba-fca6-48f5-be91-94c147f517f3.filesusr.com/ugd/c71970_77c41c3d05ef4efcaab245c732fa0c63.pdf

 

6) 上別府圭子, 他 : 日本の医療機関といわゆる院内学級における小児がん患者の復学に向けた取り組み : 質問紙調査による現状分析. 日小児血がん会誌 71 : 79-85, 2012

 

P.332 掲載の参考文献

1) Thompson RH, 他 (著), 小林登 (監), 野村みどり (監訳) : 入院する子どもにとっての遊びの重要性. 病院におけるチャイルドライフ-子どもの心を支える "遊び" プログラム. 中央法規, 85, 2000

 

2) Committee on Hospital Care and Institute for Patient and Family-centered Care : Patient-and family-centered care and the pediatrician's role. Pediatrics 129 : 394-396, 2012

PubMed

3) Goldberger J, et al. : Psychological Preparation and Coping. In : Thompson RH (ed.), The Handbook of Child Life : A Guide for Pediatric Psychosocial Care. Charles C Thomas Publisher, 30, 2009

 

4) Mahan CC : Preparing Children for Health-Care Encounters. In : Rollins JH, et al. Meeting Children's Psychosocial Needs Across the Health-Care Continuum. Pro-Ed, 22, 2005

 

Komiske BK : Institute for Family Centered Care. In : Komiske BK, Designing the World's Best Children's Hospital. Images Publishing, 2005.

 

谷川弘治, 他 (編) : 心理社会的支援サービスの諸原則と領域. 病気の子どもの心理社会的支援入門. 80-84, ナカニシヤ出版, 2004

 

P.335 掲載の参考文献

1) Tsumura A, et al. : Reliability and validity of a Japanese version of the psychosocial assessment tool for families of children with cancer. Jpn J Clin Oncol 50 : 296-302, 2020

PubMed

2) 入江亘, 他 : 慢性疾患を抱える子どもをもつ家族の夫婦サブシステムにおける心的外傷後成長と心的外傷後ストレス症状の関連. 家族看護研究 26 : 141-150, 2021

 

3) 入江亘, 他 : 小児がんで入院している子どもの父親が抱く入院生活の中での関心事. 小児保健研究 79 : 66-73, 2020

Medical*Online

4) 尾形明子 : 小児がん患児の母親の心理的苦痛と養育態度. 深田博己 (監), 臨床心理学 (心理学研究の新世紀 4), ミネルヴァ書房, 375-384, 2012

 

5) 細谷亮太 (監) : 小児がんの子どものきょうだいたち. 小児がんの子どものきょうだいのガイドライン作成委員会, 2017 http://www.ccaj-found.or.jp/materials_report/cancer_material/

 

6) 小澤美和 : 小児がん患児のきょうだいの課題 保健の科学 61 : 86-90, 2019

Medical*Online

P.338 掲載の参考文献

1) National Society of Genetic Counselors' Definition Task Force, et al. : A new definition of Genetic Counseling : National Society of Genetic Counselors' Task Force report. J Genet Couns 15 : 77-83, 2006

PubMed

2) 田村智英子 : 新しい遺伝カウンセリングのあり方を考える. 水谷修紀 (監), 遺伝診療をとりまく社会. ブレーン出版, 79-92, 2007

 

3) 日本医学会 : 医療における遺伝学的検査・診断に関するガイドライン. 日本医学会, 2011 http://jams.med.or.jp/guideline/genetics-diagnosis.html

 

4) 新川詔夫 (監), 福島義光 (編), 遺伝カウンセリングマニュアル. 第2版, 南江堂, 2003

 

5) Pagon RA, et al. (eds.) : GeneReviews. University of Washington, 2015 http://www.ncbi.nlm.nih.gov/books/NBK1116/

 

6) Stiller CA : Epidemiology and genetics of childhood cancer. Oncogene 23 : 6429-6444, 2004

PubMed

P.345 掲載の参考文献

1) Rothman DJ : Strangers at the bedside : a history of how law and bioethics transformed medical decision making. Basic Books, 1991

 

2) Tom L, et al. : Childress : Principles of Biomedical Ethics, 8th edition. Oxford Univ Press, 2019

 

3) Emanuel EJ, et al. : An Ethical Framework for Biomedical Research. In Emanuel EJ, et al., eds. The Oxford textbook of Clinical Research Ethics. Oxford University Press, 123-135, 2008

 

4) U. S. Department of Health and Human Services : Code of Federal Regulations, Title 45 CFR46, Subpart D "additional protections for research with children". HHS regulations for the protection of human subjects in research at 45CFR46 https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/common-rule-subpart-d/index.html〔2021年11月アクセス〕

 

5) Council for international organizations of medical sciences (CIOMS). International ethical guidelines for Biomedical research involving human subjects. 2002 https://cioms.ch/publications/product/international-ethical-guidelinesfor-biomedical-research-involving-human-subjects-2/〔2021年11月アクセス〕

 

6) International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use : ICH harmonised tripartite guideline. ich harmonised tripartite guideline clinical investigation of medicinal products in the pediatric population. Efficacy 11. 2000

 

7) 人を対象とする生命科学・医学系研究に関する倫理指針 (文部科学省・厚生労働省・経済産業省告示 第1号, 令和3年3月23日) 及び人を対象とする生命科学・医学系研究に関する倫理指針ガイダンス (文部科学省・厚生労働省・経済産業省, 令和3年4月16日制定) https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html〔2021年11月アクセス〕

 

8) 厚生労働省 : 臨床研究法の基本理念に基づく認定臨床研究審査委員会の審査の視点. 「臨床研究法について」認定臨床研究審査委員会 (CRB : Certified Review Board) について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000163417.html 〔2021年11月アクセス〕

 

Emanuel EJ, et al. : What makes clinical research ethical? JAMA 283 : 2701-2711, 2000

PubMed

Emanuel EJ, et al. : What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis 189 : 930-937, 2004

 

P.348 掲載の参考文献

1) 堀部敬三, 他 : 小児造血器腫瘍の診断の手引き. 日本医学館, 2012

 

2) 清河信敬, 他 : 細胞処理と検体保存ならびに検体供給システム. 小児外科 47 : 107-109, 2015

Medical*Online

3) 中澤温子 : 検体の取り扱いと病理. 小児外科 47 : 110-113, 2015

Medical*Online

4) 日本病理学会ゲノム診療用病理組織検体取扱い規程策定ワーキンググループ : ゲノム診療用病理組織検体取扱い規程. 日本病理学会, 2018

 

5) 国立大学法人京都大学大学院医学研究科, 国立研究開発法人日本医療研究開発機構 : 「ゲノム医療における情報伝達プロセスに関する提言-その1 : がん遺伝子パネル検査を中心に (改定第2版) 」及び「ゲノム医療における情報伝達プロセスに関する提言-その2 : 次世代シークエンサーを用いた生殖細胞系列網羅的遺伝学的検査における具体的方針 (改定版) 」の公開 https://www.amed.go.jp/news/seika/kenkyu/20200121.html

 

P.351 掲載の参考文献

1) Amrhein V, et al. : Scientists rise up against statistical significance. Nature 567 : 305-307, 2019

PubMed

2) 人を対象とする生命科学・医学系研究に関する倫理指針 (令和3年文部科学省・厚生労働省・経済産業省告示 第1号). https://www.mhlw.go.jp/content/000757566.pdf

 

3) 人を対象とする生命科学・医学系研究に関する倫理指針 ガイダンス (文部科学省・厚生労働省・経済産業省), 令和3年4月16日制定 https://www.mhlw.go.jp/content/000769923.pdf

 

4) 研究に関する指針について (厚生労働省ホームページ内) https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/index.html

 

P.354 掲載の参考文献

1) 臨床研究法 (平成29年法律 第16号). https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000163413.pdf

 

2) 人を対象とする生命科学・医学系研究に関する倫理指針 (令和3年文部科学省・厚生労働省・経済産業省告示 第1号). https://www.mhlw.go.jp/content/000757566.pdf

 

3) 浜島信之 : 無作為割付臨床試験. 癌と化学療法社, 11-13, 1993

 

4) 大橋靖雄 (監) : 臨床試験データマネージメント : データ管理の役割と重要性. 医学書院, 26-29, 2004

 

5) Hulley SB, 他 (著), 木原雅子, 他 (訳) : 医学的研究のデザイン : 研究の質を高める疫学的アプローチ. 第4版, メディカル・サイエンス・インターナショナル, 297-299, 2014

 

P.357 掲載の参考文献

1) Johns A : The birth of scientific reading. Nature 409 : 287, 2001

PubMed

2) 山崎茂明 : 科学者の発表倫理 : 不正のない論文発表を考える. 丸善出版, 2013

 

P.359 掲載の参考文献

1) 真部淳 : 英語論文の書き方. 日小児会誌 117 : 1709-1712, 2013

 

2) 真部淳 : 英語論文の書き方. 日小児会誌 119 : 1728-1732, 2015

 

3) 真部淳 : 英語の論文 : 査読者のコメントへの対応のポイント-採択を勝ち取るために-. 日小児会誌 125 : 397-400, 2021

 

第II部 各論 ( 疾患 )

P.365 掲載の参考文献

1) Camaschella C. : Iron-Deficiency Anemia. N Engl J Med 372 : 1832-1843, 2015

PubMed

2) World Health Organization : Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, 2011

 

3) World Health Organization : WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva, 2020

 

4) 新生児に対する鉄剤投与のガイドライン 2017. 日新生児成育医会誌 31 : 159-185, 2019

 

P.367 掲載の参考文献

1) Granz T : Anemia of Inflammation. N Engl J Med 381 : 1148-1157, 2019

 

2) Kong WN. et al. : Hepcidin and sports anemia. Cell Biosci 4 : 19, 2014

 

3) 日本透析医学会 : 慢性腎臓病患者における腎性貧血治療のガイドライン 2015年版. 透析会誌 49 : 89-158, 2015

 

4) 日本腎臓学会 : HIF-PH阻害薬適正使用に関するrecommendation. 日腎会誌 62 : 711-716, 2020

 

P.371 掲載の参考文献

1) Young NS. : Aplastic Anemia. N Engl J Med 379 : 1643-1656, 2018

PubMed

2) Yoshida N, et al. : Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure : fludarabine/melphalan vs. fludarabine/cyclophosphamide. Bone Marrow Transplant 55 : 1272-1281, 2020

PubMed

3) Kudo K, et al. : Unrelated cord blood transplantation in aplastic anemia : is anti-thymocyte globulin indispensable for conditioning? Bone Marrow Transplant 52 : 1659-1661, 2017

PubMed

4) Scheinberg P, et al. : Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365 : 430-438, 2011

PubMed

5) Narita A, et al. : Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia. Br J Haematol 187 : 227-237, 2019

PubMed

P.375 掲載の参考文献

1) 小島勢二 : 先天性骨髄不全症候群. 難治性貧血の診療ガイド編集員会 (編), 難治性貧血の診療ガイド. 南江堂, 195-236, 2011

 

2) Shimamura A, et al. : Pathology and management of inherited bone marrow failure syndrome. Blood (reviews) 24 : 101-122, 2010

 

3) 日本小児血液・がん学会 (編) : 先天性骨髄不全症ガイドライン 2017. 診断と治療社, 2017

 

4) 三谷絹子 (編) : 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 特発性造血障害に関する調査研究班. 特発性造血障害疾患の診療の参照ガイド (令和元年度改訂版). 2020 http://zoketsushogaihan.umin.jp/resources.html

 

P.380 掲載の参考文献

1) 大賀正一, 他 : 新生児の遺伝性溶血性貧血-遺伝子診断の臨床的意義. 臨血 61 : 484-490, 2020

 

2) 菅野仁, 他 : 日本におけるグルコース-6-リン酸脱水素酵素異常症. 臨血 56 : 771-777, 2015

 

3) 菅野仁, 他 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62, in press, 2021

 

4) Suzuki T, et al. : A novel α-spectrin pathogenic variant in trans to α-spectrin LELY causing neonatal jaundice with hemolytic anemia from hereditary pyropoikilocytosis coexisting with Gilbert Syndrome. J Pediatr Hematol Oncol 43 : e250-e254, 2021

 

5) Bianchi P, et al. : Diagnostic power of laboratory tests for hereditary spherocytosis : a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 97 : 516-523, 2012

PubMed

6) Hamada M, et al. : Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. Int J Hematol 108 : 306-311, 2018

PubMed

7) Andolfo I, et al. : Gain-of-function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP/SMADs pathway. Am J Hematol 95 : 188-197, 2020

PubMed

8) Grace RF, et al. : Safety and efficacy of mitapivat in pyruvate kinase deficiency. N Engl J Med 381 : 933-944, 2019 ;

PubMed

9) van Straaten S, et al. : Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. Haematologica 103 : e82-e86, 2018

PubMed

P.384 掲載の参考文献

1) Higgs DR, et al. : The biology of the thalassemia. In : Weatherall DJ, et al. (eds.), The Thalassemia Syndromes. 4th ed, Blackwell Science, 65-286, 2001

 

2) Steinber MH, et al. : Unstable hemogoobins, hemoglobins with altered oxygen affinity, hemoglobin M and other variants of clinical and biological interest. In Steinber MH, et al. (eds.), Disorders of Hemoglobin. 2nd ed., Cambridge University Press, 589-606, 2009

 

3) 山城安啓, 他 : ヘモグロビン異常症. 門脇孝, 他 (編), カラー版 内科学. 西村書店, 1370-1371, 2012

 

4) Shibata S, et al. : Abnormal hemoglobins in Japan. Hemoglobin 4 : 395-408, 1980

PubMed

5) Cavazzana-Calvo M, et al. : Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemia. Nature 467 : 318-322, 2010

 

P.389 掲載の参考文献

1) Bakkeheim E, et al. : Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate. Acta Paediatr 98 : 1896-1901, 2009

PubMed

2) 廣川誠 : 骨髄不全ガイドライン. 臨床血液 54 : 1585-1595, 2013

 

3) Gibson BE, et al. : Transfusion guidelines for neonates and older children. Br J Haematol 124 : 433-453, 2004

PubMed

4) Ohlsson A, et al. : Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 4 : CD004863, 2014

 

5) 楠田聡, 他 : 早産児に対する鉄剤投与のガイドライン. 周産期医学 36 : 767-778, 2006

 

6) Berglund SK, et al. : Effects of iron supplementation of LBW infants on cognition and behavior at 3 years. Pediatrics 131 : 47-55, 2013

PubMed

7) Berglund SK, et al. : Effects of iron supplementation of low-birth-weight infants on cognition and behavior at 7 years : a randomized controlled trial. Pediatr Res 83 : 111-118, 2018

 

厚生労働省難治性疾患克服研究事業 平成24年度難治性疾患研究班 : 「遺伝性貧血の病態解明と診断法の確立に関する研究」研究班報告書. 厚生労働省, 2012

 

P.393 掲載の参考文献

1) 三谷絹子 (編) : 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班. 自己免疫性溶血性貧血 診療の参照ガイド (令和1年改訂). 2020

 

2) Hill QA, et al. : The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 176 : 395-411, 2017

PubMed

3) Ladogana S, et al. : Diagnosis and management of newly diagnosed childhood autoimmunehaemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. Blood Transfus 15 : 259-267, 2017

 

P.397 掲載の参考文献

1) 三谷絹子 (編) : 厚生労働科学研究費補助金 (難治性疾患等政策研究事業). 特発性造血障害に関する調査研究班. 発作性夜間ヘモグロビン尿症診療の参照ガイド (令和1年改訂版). 2020

 

2) 厚生労働科学研究費補助金 (難治性疾患政策研究事業). 血液凝固異常症等に関する研究班TTPグループ (編) : 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2020. 2020

 

3) 非典型溶血性尿毒症症候群診断基準改訂委員会 (編) : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日腎会誌 58 : 62-75, 2016

 

P.401 掲載の参考文献

1) Lerner NB : Diseases of the Blood. In : Kliegman RM (eds.), Nelson Textbook of Pediatrics. 19th ed, Saunders Elsevier, 1648-1655, 2011

 

2) 片山直之 : 巨赤芽球性貧血. 金倉譲 (編), 血液診療エキスパート 貧血. 中外医学社, 91-99, 2010

 

3) Stabler SP : Clinical practice. Vitamin B12 deficiency. N Engl J Med 368 : 149-160. 2013

PubMed

4) 張替秀郎 : 巨赤芽球性貧血. 日本血液学会 (編), 血液専門医テキスト. 南江堂, 159-162, 2011

 

5) Bolaman Z, et al. : Oral versus intramuscular cobalamin treatment in megaloblastic anemia : a single center, prospective, randomized, open-label study. Clin Ther 25 : 3124-3134, 2003

PubMed

P.404 掲載の参考文献

1) 福永慶隆 : 貧血. 五十嵐隆, 他 (編). 今日の小児診断指針. 第4版, 医学書院, 107-112, 2004

 

2) Kiratli PO, et al. : Detection of ectopic gastric mucosa using 99mTc pertechnetate : review of the literature. Ann Nucl Med 23 : 97-105, 2009

PubMed

3) Hayakawa J, et al. : Successful coil embolization for life-threatening hemorrhage in childhood leukemia induction therapy. Pediatr Int 248-251, 2013

PubMed

4) Kato S, et al. : The prevalence of Helicobacter pylori in Japanese children with gastritis or peptic ulcer disease. J Gastroenterol 39 : 734-738, 2004

 

5) Hiwarkar P, et al : Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood 129 : 2033-2037, 2017

PubMed

6) 厚生労働省医薬・生活衛生局 : 血液製剤の使用指針 平成31年3月, 2019

 

P.407 掲載の参考文献

1) 厚生労働省 ; 日本人の食事摂取基準 (2020年版). https://www.mhlw.go.jp/content/10904750/000586553.pdf. (2021年4月現在)

 

2) Corbo. MD, et al. : Zinc deficiency and its management in the pediatric population : a literature review and proposed etiologic classification. J Am Acad Dermantol 69 : 616-624, 2013

PubMed

3) Itsumura N, et al. : Compound heterozygous mutations in SLC30A2/ZnT2 results in low milk zinc concentrations : a novel mechanism for zinc deficiency in a breast-fed infant. PLoS One 8 : e64045, 2013.

 

4) 湧上聖 : 微量元素欠乏 (亜鉛・銅) の病態と治療. 日本臨床 75 (増刊号 1 貧血学) : 222-225, 2017

 

5) 日本栄養臨床学会 (編) : 亜鉛欠乏症の診断指針 2018. 日本栄養臨床学会, 2018. http://www.jscn.gr.jp/pdf/aen20180402.pdf

 

6) 張替秀郎 : 血液診療エキスパート. 金倉譲 (編) : 薬剤性貧血. 中外医学社, p.273-280, 2010

 

7) 半下石明 : 新戦略による貧血治療. 金倉譲 (編) : 薬剤性貧血. 中山書店, p.273-280, 2014

 

P.409 掲載の参考文献

1) Cario H, et al. : Erythrocytosis in children and adolescents-classification, characterization, and consensus recommendations for the diagnostic approach. Pediatr Blood Cancer 60 : 1734-1738, 2013

PubMed

2) Ismael O, et al. : Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer 59 : 530-535, 2012

PubMed

3) Zhan, H, et al. : The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol 7 : 334-342, 2009

PubMed

4) Kucine N : Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep 15 : 141-148, 2020

 

5) Verstovsek S, et al. : A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120 : 513-520, 2014

PubMed

P.413 掲載の参考文献

1) Michniacki TF, et al. : Leukopenia. In : Kliegman RM, et al. (eds.), Nelson Textbook of Pediatrics. 20th ed, Elsevier, 1141-1147, 2019

 

2) Tangye SG, et al. : Human inborn errors of immunity : 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40 : 24-64, 2020

 

P.416 掲載の参考文献

1) Lanzkowsky P, et. al. (eds.) : Lanzkowsky's Mannual of Pediatric Hematology and Oncology. 6th ed, 709-728, 2016

 

2) Sasaki H, et al. : Regulation of basophil and mast cell development by transcription factors. Allergol Int 65 : 127-134, 2016

PubMed

3) O'Connell EM, et al. : Eosinophilia in Infectious Diseases. Immunol Allergy Clin North Am 35 : 493-522, 2015

PubMed

4) Williams KW, et al. : Hypereosinophilia in Children and Adults : A Retrospective Comparison. J Allergy Clin Immunol Pract 4 : 941-947, 2016

PubMed

5) Arber DA, et al. : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 : 2391-2405, 2016

 

P.419 掲載の参考文献

1) Guilliams M, et al. : Dendritic cells, monocytes and macrophages : a unified nomenclature based on ontogeny. Nat Rev Immunol 14 : 571-578, 2014

PubMed

2) Miah M, et al. : Prenatal Development and Function of Human Mononuclear Phagocytes. Front Cell Dev Biol 9 : 649937, 2021

PubMed

3) Guilliams M, et al. : Developmental and Functional Heterogeneity of Monocytes. Immunity 49 : 595-613, 2018

PubMed

4) Collin M, et al. : Human dendritic cell subsets : an update. Immunology 154 : 3-20, 2018

PubMed

5) Bigley V, et al. : Collin M. Human dendritic cell immunodeficiencies. Semin Cell Dev Biol 86 : 50-61, 2019

PubMed

P.421 掲載の参考文献

Ochs HD, et al. : Primary immunodeficiency disease : A molecular and genetic approach. 3rd ed., Oxford University Press, 2014

 

P.426 掲載の参考文献

1) Thrasher AJ : WASP in immune-system organization and function. Nat Rev immunol 2 : 635-646, 2002

PubMed

2) Schwinger W, et al. : The phenotype and treatment of WIP deficiency : literature synopsis and review of a patient with pre-transplant serial donor lymphocyte infusions to eliminate CMV. Front Immunol 9 : 2554, 2018

PubMed

3) Kahr WHA, et al. : Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. Nature Commun 8 : 14816, 2017

 

4) Perlman S, et al. : Ataxia-telangiectasia : diagnosis and treatment. Semin Pediatr Neurol 10 : 173-182, 2003

PubMed

5) Lisa JK, et al. : Velocardiofacial syndrome, DiGeorge syndrome : the chromosome 22q11.2 deletion syndromes. Lancet 370 : 1443-1452, 2007

 

6) Minegishi Y, et al. : Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 : 1058-1062, 2007

PubMed

P.429 掲載の参考文献

1) Smith T, Cunningham-Rundles C : Primary B-cell immunodeficiencies. Hum Immunol 80 : 351-362, 2019.

PubMed

2) Tangye SG, et al. : Human inborn errors of immunity : 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40 : 24-64, 2020.

 

3) Ishimura M, et al. : Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol 31 : 968-976, 2011.

PubMed

4) Bousfiha AA, et al. : A phenotypic approach for IUIS PID classification and diagnosis : guidelines for clinicians at the bedside. J Clin Immunol 33 : 1078-1087, 2013.

PubMed

5) Bonagura VR, et al. : Biologic IgG level in primary immunodeficiency disease : the IgG level that protects against recurrent infection. J Allergy Clin Immunol 122 : 210-212, 2008.

PubMed

6) Nakagawa N, et al. : Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 128 : 223-225.e2, 2011.

 

P.431 掲載の参考文献

1) Canna SW, et al. : Pediatric hemophagocytic lymphohistiocytosis. Blood 135 : 1332-1343, 2020

PubMed

2) Ishii E, et al. : Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86 : 58-65, 2007

PubMed

3) Smits BM, et al. : A minimal parameter set facilitating early decision-making in the diagnosis of hemophagocytic lymphohistiocytosis. J Clin Immunol 41 : 1219-1228, 2021

PubMed

4) Ishimura M, Ohga S. submitted.

PubMed

5) Bergsten E, et al. : Stem cell transplantation for children with hemophagocytic lymphohistiocytosis : results from the HLH-2004 study. Blood Adv 4 : 3754-3766, 2020

 

P.435 掲載の参考文献

1) 布井博幸, 他 : 慢性肉芽腫症. 日本免疫不全研究会 (編), 原発性免疫不全症候群 診療の手引き. 初版, 診断と治療社, 98-103, 2017

 

2) Anjani G, et al. : Recent advances in chronic granulomatous disease. Genes Dis 7 : 84-92, 2019

PubMed

3) Kohn DB, et al. : Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med 26 : 200-206, 2020

PubMed

4) Yanagimachi M, et al. : Hematopoietic cell transplantation for chronic granulomatous disease in japan. Front Immunol 11 : 1617, 2017

 

5) Gungor T, et al. : Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease : a prospective muticentre study. Lancet 383 : 436-448, 2014

 

6) Fernandes JF, et al. : Outcomes after haploidentical stem cell transplantation with post transplantation cyclophosphamide in paitents with primary immunodeficiency diseases. Biol Blood Marrow Transplant 26 : 1923-1929, 2020

 

P.438 掲載の参考文献

1) Tangye SG, et al. : Human inborn errors of Immunity : 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol 40 : 26-69, 2020

 

2) Picard C, et al. : Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 24 : 490-497, 2011

PubMed

3) Betrains A, et al. : Systemic autoinflammatory disease in adults. Autoimmun Rev 20 : 102774, 2021

PubMed

4) 日本小児リウマチ学会 (編) : 自己炎症性疾患診療ガイドライン 2017, 診断と治療社, 2017

 

5) Soriano A, et al. : Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome : Evidence-Based Approach and Proposal of a Practical Guide. Front Immunol 11 : 865, 2020

PubMed

P.441 掲載の参考文献

1) Tedesco F : Inherited complement deficiencies and bacterial infections. Vaccine 26 Suppl 8 : I3-18, 2008

 

2) Lintner KE, et al. : Early components of the compliment classical activation pathway in human systemic autoimmune diseases. Front Immunol 7 : 36, 2016

 

3) Inai S, et al : Inherited deficiencies of the late-acting complement components other than C9 found among healthy blood-donors. International Archives of Allergy and Applied Immunology 90 : 274-279, 1989

PubMed

4) Fukumori Y, et al : A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. International Immunology 1 : 85-89, 1989

PubMed

P.446 掲載の参考文献

1) 2020年度厚生労働省科学研究費補助金エイズ対策研究事業HIV感染症及びその合併症の課題を克服する研究班 : 抗HIV治療ガイドライン 2021年3月. 2021

 

2) Manohar R, et al. : Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340 : 1614-1622, 1999

 

3) 日本小児感染症学会 : 日常診療に役立つ小児感染症マニュアル 2017. 東京医学社, 406-412, 2017

 

4) 森内昌子, 他 : HIV感染症. 小児科診療 74 : 1379-1384, 2011

Medical*Online

5) De Cock KM, et al. : Prevention of mother-to-child HIV transmission in resource-poor countries : translating research into policy and practice. JAMA 283 : 1175-1182, 2000

PubMed

6) UNAIDS FACT SHEET-WORLD AIDS DAY 2020 https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

 

7) 令和2年度厚生労働科学研究費補助金エイズ対策政策研究事業「HIV感染者の妊娠・出産・予後に関する疫学的・コホート的調査研究と情報の普及啓発法の開発ならびに診療体制の整備と均てん化に関する研究. 令和2年度総括・分担研究報告書, 2021年3月

 

8) 2020年度厚生労働科学研究費補助金エイズ対策政策研究事業「HIV感染者の妊娠・出産・予後に関する疫学的・コホート的調査研究と情報の普及啓発法の開発ならびに診療体制の整備と均てん化に関する研究」班 : HIV感染妊娠に関する診療ガイドライン (第2版) 2021年3月. 2021

 

9) CDC : 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43 (RR-12) : 1-10, 1994

 

10) Guidelines for the use of antiretroviral agents in pediatric HIV infection. Dec 30, 2021. https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv

 

11) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Oct. 25, 2019 https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection

 

P.449 掲載の参考文献

1) 日本小児血液・がん学会 (編) : 2022年小児免疫性血小板減少症診療ガイドライン. 日小児血がん会誌 (印刷中), 2022

 

2) 小児血液・がん学会疾患登録委員会 : 小児がん学会全数把握事業・小児血液学会血液疾患疫学調査研究2009年から2011年診断例の2012年度集計. 日小児血がん会誌 50 : 462-478, 2013

Medical*Online

3) Shirahata A, et al. : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009

PubMed

4) Kurata Y, et al. : Epidemiology of primary immune thrombocytopenia in children and adults in Japan : a population-based study and literature review. Int J Hematol 93 : 329-335, 2011

PubMed

5) 今泉益栄 : 特発性 (免疫性) 血小板減少性紫斑病の診断と治療-ITPの新たな展開. 日小児会誌 121 : 1937-1944, 2017

 

6) Kashiwagi H, et al. : Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 98 : 24-33, 2013

PubMed

7) Rodeghiero F, et al. : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009

 

8) Neunert C, et al. : American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3386, 2019

PubMed

9) 高橋幸博, 他 : 小児難治性ITP治療ガイド 2019. 日小児血がん会誌 56 : 61-68, 2019

Medical*Online

10) Schoettler ML, et al. : Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP(R)). Pediatr Blood Cancer 64 : 10, 2017

 

11) Kitazawa J, et al. : Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination : Retrospective survey of a nationwide disease registry. Int J Hematol 115 : 114-122, 2022

PubMed

12) Klaassen RJ, et al. : Quality of life in childhood immune thrombocytopenia : international validation of the Kid's ITP tools. Pediatr Blood Cancer 60 : 95-100, 2013

 

13) 笹原洋二 : ITPと鑑別が必要な小型・正常大の血小板を有する遺伝性血小板減少症. 日小児血がん会誌 53 : 311-316, 2015

 

P.452 掲載の参考文献

1) Harrison CN, et al. : Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149 : 352-375, 2010

PubMed

2) Kucine N, et al. : Primary thrombocytosis in children. Haematologica 99 : 620-628, 2014

PubMed

3) Ameena M, et al. : Essential Thrombocythemia in Children : A Retrospective Study. J Haematol 10 : 106-113, 2021

 

4) Dame C, et al. : Primary and secondary thrombocytosis in childhood. Br J Haematol 129 : 165-177, 2005

PubMed

5) Dror Y, et al. : Essential thrombocythaemia in children. Br J Haematol 107 : 691-698, 1999

PubMed

6) Beer PA, et al. : How I treat essential thrombocythemia. Blood 117 : 1472-1482, 2011

 

7) Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasmas and acute leukemia. Blood Cancer Journal 127 : 2391-2405, 2016

 

8) Stockklausner C, et al. : Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. Ann Hematol 100 : 1647-1665, 2021

PubMed

P.456 掲載の参考文献

1) 國島伸治 : 先天性血小板減少症. 臨床血液 59 : 764-773, 2018

 

2) 金子誠 : 解明されつつある血小板機能異常症の分子病態-先天性血小板機能異常症の解析から-. 血栓止血誌 23 : 457-464, 2012

 

3) 國島伸治 : 先天性血小板機能異常症-ベルナール・スーリエ症候群と血小板無力症-. 検査と技術 42 : 102-107, 2014

 

P.462 掲載の参考文献

1) 厚生労働省委託事業 血液凝固異常症全国調査 令和3年度報告書 (天野景裕委員長)

 

2) 日本止血学会 インヒビターのない血友病患者に対する止血治療ガイドライン作成委員会 (藤井輝久, 他) : 日本血栓止血学会 インヒビターのない血友病患者に対する止血治療ガイドライン : 2013年改訂版. 日血栓止血会誌 24 : 619-639, 2013 http://www.jsth.org/committee/pdf/03_inhibitor_H1_B.pdf

 

3) Manco Johnson MJ, et al. : Prophylaxis versus Episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357 : 535-544, 2007

PubMed

4) 日本血栓止血学会 インヒビター保有先天性血友病患者に対する止血治療ガイドライン作成委員会 (酒井道生, 他) : インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 日血栓止血会誌 24 : 640-658, 2013 http://www.jsth.org/committee/pdf/03_inhibitor_H1_A.pdf

 

5) Leissinger CA, et al. : Anti-Inhibitor coagulant complex prophylaxis in Hemophilia with inhibitor. N Engl J Med 365 : 1684-1692, 2011

 

6) Hay CRM, et al. : The principal results of the International Immune Tolerance Study : a randomized dose comparison. Blood 119 : 1335-1344, 2012

PubMed

7) Shima M et al. FVIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 374 : 2044-2053, 2016.

 

P.464 掲載の参考文献

1) 高橋芳右 : von Willebrand病の治療はどのようにすればよいか? 押味和夫 (編), EBM血液疾患の治療. 中外医学社, 592-601, 2002

 

2) 高橋芳右 : von Willebrand病. 白幡 聡 (編), みんなに役立つ血友病の基礎と臨床, 医薬ジャーナル社, 158-163, 2009

 

P.465 掲載の参考文献

1) Franchini M, et al. : Rare congenital bleeding disorders. Ann Transl Med 6 : 331, 2018

PubMed

2) 血液凝固異常症全国調査委員会 : 厚生労働省委託事業 血液凝固異常症全国調査 令和2年度報告書. エイズ予防財団, 2021

 

P.467 掲載の参考文献

1) 白幡聡 : ビタミンK依存凝固因子異常. 浅野茂隆, 他 (監), 三輪血液病学. 文光堂, 1730-1735, 2006

 

2) Araki S, et al. : Vitamin K deficiency bleeding in infancy. Nutrients 12 : 780, 2020. doi : 10.3390/nu12030780

 

3) Shearer MJ : Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev 23 : 49-59, 2009

PubMed

4) 白幡聡, 他 : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌 115 : 705-712, 2011

 

5) 早川昌弘, 森岡一朗, 東海林宏道, 他 : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の現状調査 日本小児科学会雑誌 125 : 99-101, 2021

 

P.470 掲載の参考文献

1) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌2 0 : 77-113, 2009

 

2) 中川雅夫 : 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液凝固異常症調査研究班 平成10年度研究報告書. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会, 57-72, 1999

 

3) DIC診断基準作成委員会 : 日本血栓止血学会DIC診断基準 2017年版. 日血栓止血会誌 28 : 369-391, 2017

 

4) 新生児DIC診断・治療指針作成ワーキンググループ (編) : 新生児DIC診断・治療指針 2016年版. 日産婦新生児血会誌 25 : 3-34, 2016

 

P.472 掲載の参考文献

1) 後天性血友病A 診療ガイドライン作成委員会 : 後天性血友病 A 診療ガイドライン. 日血栓止血会誌 22 : 295-322, 2011

 

2) Collins PW, et al. : Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109 : 1870-1877, 2007

PubMed

3) 田中一郎, 他 : わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 日血栓止血会誌 19 : 140-153, 2008

 

4) Collins PW, et al. : Diagnosis and management of acquired coagulation inhibitors : a guideline from UKHCDO. Br J Haematol 162 : 758-773, 2013

 

5) 嶋緑倫 : 後天性血友病・後天性von Willebrand病の診断と治療. 日本血栓止血学会編集委員会 (編), わかりやすい血栓と止血の臨床. 南江堂, 91-95, 2011

 

P.475 掲載の参考文献

1) 大賀正一, 他 : 早発型血栓症の遺伝性素因-診断と治療管理の課題. 臨床血液 61 : 1373-1381, 2020

 

2) Ishiguro A, et al. : Pediatric thromboembolism : a national survey in Japan. Int J Hematol 105 : 52-58, 2017

PubMed

3) Ichiyama M, et al. : Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism. Pediatr Res 79 : 81-86, 2016

PubMed

P.478 掲載の参考文献

1) 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 血液凝固異常症等に関する研究班 : 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2020 https://www.naramed-u.ac.jp/~trans/news/pdf/ttp.pdf〔2021年3月11日アクセス〕

 

2) 芦田明 : 志賀毒素産生腸管出血性大腸菌関連溶血性尿毒症症候群 (STEC-HUS). 血栓止血誌 31 : 37-44, 2020

 

3) 加藤規利, 他 : aHUSの病態と臨床. 日血栓止血会誌 31 : 45-54, 2020

 

4) 日本腎臓学会・日本小児科学会合同「非典型溶血性尿毒症症候群診断基準作成委員会」 : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド, 2013 https://jsn.or.jp/guideline/pdf/ahus_2016-2.pdf〔2021年3月11日アクセス〕

 

5) Wincup C, et al. : The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome. Front Pediatr 6 : 362, 2018

PubMed

P.481 掲載の参考文献

1) Caruso V, et al. : Thrombotic complications in childhood acute lymphoblastic leukemia : a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108 : 2216-2222, 2006.

PubMed

2) Greiner J, et al. : THROMBOTECT-a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Hematologica 756 : 756-765, 2019.

 

3) Cuker A, et al. : American Society of Hematology 2018 guidelines for management of venous thromboembolism : heparin-induced thrombocytopenia. Blood Adv 2 : 3360-3392, 2018.

PubMed

4) Vincent JL, et al. : Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy : The SCARLET randomized clinical trial. JAMA 321 : 1993-2002, 2019.

PubMed

P.491 掲載の参考文献

1) Horibe K, et al. : Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 98 : 74-88, 2013

PubMed

2) Pui CH, et al. : Pediatric acute lymphoblastic leukemia : where are we going and how do we get there? Blood 120 : 1165-1174, 2012

PubMed

3) Pui CH, et al. : Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 16 : 227-240, 2019.

PubMed

4) Hunger SP, et al. : Acute Lymphoblastic Leukemia in Children. N Engl J Med 373 : 1541-1552, 2015

PubMed

5) Inaba H, et al. : Pediatric acute lymphoblastic leukemia. Haematologica 105 : 2524-2539, 2020

PubMed

6) Henze G, et al. : Relapsed acute lymphoblastic leukemia. In : Pui CH (ed.), Childhood Leukemias, 2nd ed., Cambridge University Press, 473-486, 2006

 

P.497 掲載の参考文献

1) Swerdlow SH, et al. : WHO classification of tumours of haematopoietic and lymphoid tissues. revised 4th ed., IARC, 121-171, 2017

 

2) Bolouri H, et al. : The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24 : 103-112, 2018

PubMed

3) Creutzig U, et al. : Diagnosis and management of acute myeloid leukemia in children and adolescents : recommendations from an international expert panel. Blood 120 : 3187-3205, 2012

 

4) Taga T, et al. : Acute myeloid leukemia in children : Current status and future directions. Pediatr Int 58 : 71-80, 2016

PubMed

5) Moritake H, et al. : The outcomes of relapsed acute myeloid leukemia in children : Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study. Pediatr Blood Cancer 68 : e28736, 2021

 

P.501 掲載の参考文献

1) 富澤大輔 : 小児血液疾患-よくわかる最新知見. 造血器悪性疾患 乳児白血病. 小児科 55 : 1731-1736, 2014

 

2) Meyer C, et al. : The MLL recombinome of acute leukemias in 2017. Leukemia 32 : 273-284, 2018

PubMed

3) 横山明彦 : MLLキメラによる白血病発症機構. 血液内科 77 : 260-266, 2018

 

4) Andersson AK, et al. : The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 47 : 330-337, 2015

PubMed

5) Tomizawa D, et al. : Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects : a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 21 : 2258-2263, 2007

 

6) Koh K, et al. : Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia 29 : 290-296, 2015

PubMed

7) Tomizawa D, et al. : A risk-stratified therapy for infants with acute lymphoblastic leukemia : a report from the JPLSG MLL-10 trial. Blood 136 : 1813-1823, 2020

PubMed

P.503 掲載の参考文献

1) Kurosawa H, et al. : Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia : Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 63 : 406-411, 2016

 

2) Baccarani M, et al. : European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood 122 : 872-884, 2013

PubMed

3) Hochhaus A, et al. : European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34 : 966-984, 2020

PubMed

4) Shima H, et al. : Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 2022 in print

 

5) Millot F, et al. : Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase : results of the French national phase IV trial. J Clin Oncol 29 : 2827-2832, 2011

PubMed

6) Suttorp M, et al. : Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia : results from a phase III trial. Leukemia 32 : 1657-1669, 2018

PubMed

7) Millot F, et al. : Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. European Journal of Cancer 115 : 17-23, 2019

PubMed

P.507 掲載の参考文献

1) Hasle H, et al. : A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17 : 277-282, 2003

 

2) Hasegawa D, et al. : Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol 166 : 758-766, 2014

 

3) Narumi S, et al. : SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 48 : 792-797, 2016

 

4) Murakami N, et al. : Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood 131 : 1576-1586, 2018

PubMed

5) Arber DA, et al. : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 : 2391-2405, 2016

 

6) Takagi M, et al. : Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood 117 : 2887-2890, 2011

PubMed

P.511 掲載の参考文献

1) Lange B : The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 110 : 512-524, 2000

PubMed

2) Xu G, et al. : Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102 : 2960-2968, 2003

PubMed

3) Hasle H, et al. : Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood 2021011463. doi : 10.1182/blood.2021011463 [Online ahead of print]

 

4) Korbel JO, et al. : The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 106 : 12031-12036, 2009

PubMed

5) Banno K, et al. : Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities. Cell Rep 15 : 1228-1241, 2016

PubMed

6) Yuzawa K, et al. : Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21. Pediatr Blood Cancer 67 : e28188, 2020

PubMed

7) Klusmann JH, et al. : Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111 : 2991-2998, 2008

PubMed

8) Yamato G, et al. : Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. Leukemia 35 : 1480-1484, 2021

PubMed

9) Yoshida K, et al. : The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 45 : 1293-1299, 2013

PubMed

10) Kudo K, et al. : Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia : the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 25 : 5442-5447, 2007

 

11) Taga T, et al. : Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia 35 : 2508-2516, 2021

PubMed

P.515 掲載の参考文献

1) がん情報サービス : がん統計. 小児・AYA世代のがん種の内訳の変化. 国立がん研究センターがん対策情報センター, 2018 https://ganjoho.jp/reg_stat/statistics/stat/child_aya.html

 

2) National Cancer Institute : Childhood Non-Hodgkin Lymphoma Treatment (PDQ(R)) http://www.cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessional

 

3) Woessmann W, et al. : The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms : a report of the BFM Group Study NHL-BFM95. Blood 105 : 948-958, 2005

 

4) Gerrard M, et al. : Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma : results of the FAB/LMB 96 international study. Br J Haematol 141 : 840-847, 2008

 

5) Patte C, et al. : Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents : it is possible to reduce treatment for the early responding patients. Blood 109 : 2773-2780, 2007

 

6) Minard-Colin V, et al. : Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med 382 : 2207-2219, 2020

PubMed

7) Tsurusawa M, et al. : Improved treatment results of children with B-cell non-Hodgkin lymphoma : a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer 61 : 1215-1221, 2014

 

8) Burkhardt B, et al. : Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24 : 491-499, 2006

PubMed

9) Sunami S, et al. : Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma : A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63 : 451-457, 2016

 

10) Brugieres L, et al. : Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma : results of a randomized trial of the EICNHL Group. J Clin Oncol 27 : 897-903, 2009

 

11) Le Deley M-C, et al. : Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma : results of the randomized ALCL99-vinblastine trial. J Clin Oncol 28 : 3987-3993, 2010

 

12) Mori T, et al. : Analysis of Japanese registration from the randomized international trial for childhood anaplastic large cell lymphoma (ALCL99-R1). Rinsho Ketsueki 55 : 526-533, 2014

PubMed

13) Mosse YP, et al. : Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor : A Children's Oncology Group Study. J Clin Oncol 35 : 3215-3221, 2017

 

P.518 掲載の参考文献

1) 古賀友紀, 他 : 小児ホジキンリンパ腫. 日小児血液会誌 24 : 255-260, 2010

Medical*Online

2) Olweny CL : Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol 8 : 1598, 1990

 

3) 日本小児血液・がん学会 (編) : 小児白血病・リンパ腫診療ガイドライン 2016年版 (暫定案), 金原出版

 

4) Castellino SM, et al. : Morbidity and mortality in long-term survivors of Hodgkin lymphoma : a report from the Childhood Cancer Survivor Study. Blood 117 : 1806-1816, 2011

PubMed

P.522 掲載の参考文献

1) Swerdlow SH, et al. (eds.) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Revised ed., IARC press, 2017

 

2) Okuno Y, et al. : Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4 : 404-413, 2019

PubMed

3) Oliveira JB, et al. : Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS) : report from the 2009 NIH International Workshop. Blood 116 : e35-e40, 2010

PubMed

4) Yang X, et al. : SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. Pediatr Int 54 : 447-454 2012.

PubMed

P.526 掲載の参考文献

1) Rodriguez-Galindo C, et al. : Langerhans cell histiocytosis. Blood 135 : 1319-1331, 2020

PubMed

2) Morimoto A, et al. : Recent advances in Langerhans cell histiocytosis. Pediatr Int 56 : 451-461, 2014

PubMed

3) Morimoto A, et al. : Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine 97 : 73-79, 2017

PubMed

4) Hayase T, et al. : Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan. Int J Hematol 112 : 560-567, 2020

PubMed

5) Sakamoto K, et al. : Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis : Results from the JLSG-96/02 studies. Pediatr Blood Cancer 66 : e27454, 2019

PubMed

6) Morimoto A, et al. : Hematopoietic stem cell transplantation for Langerhans cell histiocytosis : clinical findings and long-term outcomes. Expert Opin Orphan Drugs 8 : 317-328, 2020

 

P.529 掲載の参考文献

1) Emile J-F, et al. : Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127 : 2672-2681, 2016

PubMed

2) Durham BH : Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25 : 1839-1842, 2019

PubMed

3) Durham BH : Molecular characterization of the histiocytoses : Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol 86 : 62-76, 2019

PubMed

4) Haroche J, et al. : Erdheim-Chester disease. Blood 135 : 1311-1318, 2020

PubMed

5) Picarsic J, et al. : BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG) : a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 7 : 168, 2019

PubMed

6) Abla O, et al. : Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131 : 2877-2890, 2018

PubMed

P.536 掲載の参考文献

1) Northcott PA, et al. : Medulloblastoma Comprises Four Distinct Molecular Variants. J Clin Oncol 29 : 1408-1414, 2011

PubMed

2) Taylor MD, et al. : Molecular subgroups of medulloblastoma : the current consensus. Acta Neuropathol 123 : 465-472, 2012

PubMed

3) Gajjar A, et al. : Pediatric Brain Tumors : Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol 33 : 2986-2998, 2015

PubMed

4) Shih DJ, et al. : Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 : 886-896, 2014

PubMed

5) Okada K, et al. : Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma : A report from the Japanese Pediatric Brain Tumor Consortium. Pediatr Blood Cancer 67 : e28572, 2020

PubMed

6) Packer RJ, et al. : Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 : 4202-4208, 2006

PubMed

7) Gajjar A, et al. : Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96) : long-term results from a prospective, multicentre trial. Lancet Oncol 7 : 813-820, 2006

PubMed

8) Rutkowski S, et al. : Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 : 978-986, 2005

PubMed

9) Cohen BH, et al. : Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. Pediatr Neurol 53 : 31-46, 2015

 

10) Dhall G, et al. : Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III : a multi-institutional, prospective clinical trial. Neuro Oncol 22 : 1862-1872, 2020

 

11) Wang L, et al. : Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511 : 241-245, 2014

PubMed

12) Calaminus G, et al. : SIOP CNS GCT 96 : final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 15 : 788-796, 2013

PubMed

13) Goldman S, et al. : Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors : A Children's Oncology Group Study. J Clin Oncol 33 : 2464-2471, 2015

PubMed

14) Calaminus G, et al. : Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol 19 : 1661-1672, 2017

 

15) Balmaceda C, et al. : Chemotherapy without irradiation-a novel approach for newly diagnosed CNS germ cell tumors : results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 14 : 2908-2915, 1996

PubMed

16) Kellie SJ, et al. : Primary chemotherapy for intracranial nongerminomatous germ cell tumors : results of the second international CNS germ cell study group protocol. J Clin Oncol 22 : 846-853, 2004

 

17) Sturm D, et al. : New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164 : 1060-1072, 2016

PubMed

18) Gerber NU, et al. : Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. Int J Radiat Oncol Biol Phys 89 : 863-871, 2014

PubMed

19) Friedrich C, et al. : Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol 15 : 224-234, 2013

PubMed

20) Fangusaro J, et al. : Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs) : report of the Head Start I and II experience. Pediatr Blood Cancer 50 : 312-318, 2008

 

21) Chintagumpala M, et al. : A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 11 : 33-40, 2009

PubMed

P.544 掲載の参考文献

Mehta MP, et al. (eds.) : Principles and Practice of Neuro-Oncology : A Multidisciplinary Approach. Demos Medical Publishing, 2010

 

Gupta N, et al. (eds.) : Pediatric CNS Tumors (Pediatric Oncology). 3rd ed, Springer, 2016

 

Scheinemann K, et al. (eds.) : Pediatric Neuro-oncology. Springer, 2015

 

Batchelor T, et al. (eds.) : Oxford Textbook of Neuro-Oncology (Oxford Textbook in Clinical Neurology). Oxford University Press, 2017

 

P.547 掲載の参考文献

1) Committee for the National Registry of Retinoblastoma : The National Registry of Retinoblastoma in Japan (1983-2014). Jpn J Ophthalmol 62 : 409-423, 2018

 

2) Knudson Jr AG : Mutation and cancer : statistical study of retinoblastoma. Proc Natl Acad Sci USA 68 : 820-823, 1971

 

3) 日本小児血液・がん学会 (編) : 小児がん診療ガイドライン 2016年版. 金原出版, 153-197, 2016

 

4) Brierley JD, 他 (編著), UICC 日本委員会TNM委員会 (訳) : TNM悪性腫瘍の分類 第8版 日本語版. 金原出版, 226-229, 2017

 

5) Kamihara J, et al. : Retinoblastoma and neuroblastoma Predisposition and Surveillance. Clin Cancer Res 23 : e98-e106, 2017

PubMed

P.551 掲載の参考文献

1) Monclair T, et al. : The International Neuroblastoma Risk Group (INRG) staging system : an INRG Task Force report. J Clin Oncol 27 : 298-303, 2009

PubMed

2) Cohn SL, et al. : The International Neuroblastoma Risk Group (INRG) classification system : an INRG Task Force report. J Clin Oncol 27 : 289-297, 2009

PubMed

3) Iehara T, et al. : Successful treatment of infants with localized neuroblastoma based on their MYCN status. Int J Clin Oncol 18 : 389-395, 2013

PubMed

4) Yu AL, et al. : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363 : 1324-1334, 2010

PubMed

P.558 掲載の参考文献

1) Lopez-Terrada D, et al. : Towards an international pediatric liver tumor consensus classification : proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 27 : 472-491, 2014

PubMed

2) Hiyama E. Pediatric hepatoblastoma : diagnosis and treatment. Transl Pediatr 3 : 293-299, 2014

PubMed

3) Towbin AJ, et al. : 2017 PRETEXT : radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 48 : 536-554, 2018

PubMed

4) Czauderna P, et al. : The Children's Hepatic tumors International Collaboration (CHIC) : Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 52 : 92-101, 2016

 

5) Meyers RL, et al. : Risk-stratified staging in paediatric hepatoblastoma : a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol 18 : 122-131, 2017

 

6) Hiyama E, et al. : Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. J Clin Oncol 38 : 2488-2498, 2020

 

7) Katzenstein HM, et al. : Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731) : a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol 20 : 719-727, 2019

 

8) Zsiros J, et al. : Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4) : a prospective, single-arm, feasibility study. Lancet Oncol 14 : 834-842, 2013

PubMed

9) Brock PR, et al. : Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl JMed 378 : 2376-2385, 2018

 

P.562 掲載の参考文献

1) Vujanic GM, et al. : Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38 : 79-78, 2002

PubMed

2) 日本病理学会小児腫瘍組織分類委員会 (編) : 小児腫瘍組織アトラス 第4巻 小児腎腫瘍. 金原出版, 2008

 

3) 越永従道 : 腎腫瘍. 日本小児腎臓病学会 (編), 小児腎臓病学. 診断と治療社, 366-374, 2012

 

4) Metzger ML, et al. : Current therapy for Wilms' tumor. Oncologist 10 : 815-826, 2005

PubMed

5) Koshinaga T, et al. : Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2) : A report from the Japan Children's Cancer Group (JCCG). Pediatr Blood Cancer 65 : e27056, 2018

 

6) Seibel NL, et al. : Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5). Pediatr Blood Cancer 66 : e27450, 2019

PubMed

7) Tomlinson GE, et al. : Rhabdoid tumor of the kidney in the National Wilms' Tumor Study : age at diagnosis as a prognostic factor. J Clin Oncol 23 : 7641-7645. 2005

PubMed

P.565 掲載の参考文献

1) 日本病理学会小児腫瘍組織分類委員会 (編) : 小児腫瘍分類図譜 第5篇 小児胚細胞腫瘍群腫瘍. 金原出版, 1999

 

2) 日本小児血液・がん学会 疾患登録委員会 : 固形腫瘍集計結果. 日本小児血液・がん学会, 2020 https://www.jspho.org/disease_record.html

 

3) 日本産婦人科学会, 日本病理学会 (編) : 卵巣腫瘍取り扱い規約 第1部 (第2版). 金原出版, 2009

 

4) Fraizer AL, et al : Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 33 : 195-201, 2015

 

5) 日本小児外科学会悪性腫瘍委員会 : 小児固形悪性腫瘍の予後 追跡調査結果の報告-2006～2010年登録症例について. 日小外会誌 54 : 1260-1293, 2018

Medical*Online

P.569 掲載の参考文献

日本整形外科学会/日本病理学会 (編) : 整形外科・病理 悪性骨腫瘍取扱い規約. 第4版, 金原出版, 92-102, 2015

 

日本小児血液・がん学会 (編) : 小児がん診療ガイドライン 2016年版, 第2版, 金原出版, 93-124, 2016

 

川井章, 他 : 肉腫-基礎・臨床の最新知見, 日本臨牀 78 : 28-46, 2020

 

WHO Classification of Tumours Editorial Board : WHO Classification of Tumours ; Soft Tissue and Bone Tumours. 5th ed., WHO, 400-421, 2020

 

P.573 掲載の参考文献

1) Grier HE, et al. : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348 : 694-701, 2003

 

2) Womer RB, et al. : Randomized controlled trial of Interval-compressed chemotherapy for the treatment of localized Ewing sarcoma : a report from the Children's Oncology Group. J Clin Oncol 30 : 4148-4154, 2012

 

3) Paulussen M, et al. : Results of EICESS-92 Study : two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide add to standard treatment in high-risk patientnts. J Clin Oncol 26 : 4385-4393, 2008

 

4) Le Deley MC, et al. : Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma : results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 32 : 2240-2248, 2014

 

5) Chin M, et al. : Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan : Results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer 67 : e28194, 2020

PubMed

6) Ladenstein R, et al. : Primary disseminated multifocal Ewing sarcoma : results of the Euro-EWING 99 trial. J Clin Oncol 28 : 3284-91, 2010

 

P.578 掲載の参考文献

1) Sultan I, et al. : Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005 : an analysis of 2,600 patients. J Clin Oncol 27 : 3391-3397, 2009

PubMed

2) Raney RB, et al. : Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life : a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 23 : 215-220, 2001

 

3) Hosoi H, et al. : A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan. Int J Clin Oncol 12 : 137-145, 2007

PubMed

4) Missiaglia E, et al. : PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30 : 1670-1677, 2012

PubMed

5) Bisogno G, et al. : Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20 : 1566-1575, 2019

PubMed

6) Spunt SL, et al. : A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332) : a Children's Oncology Group prospective study. Lancet

 

Oncol 21 : 145-161, 2020

 

P.583 掲載の参考文献

1) 日本小児血液・がん学会 : 疾患登録集計結果. 日本小児血液・がん学会ホームページ. 2020 https://www.jspho.org/disease_record.html

 

2) Enomoto Y, et al. : Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World J Surg 36 : 1241-1246, 2012

PubMed

3) Fenton CL, et al. : The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85 : 1170-1175, 2000

 

4) Glick RD, et al. : Management of pancreatoblastoma in children and young adults. J Pediatr Hematol Oncol 34 Suppl 2 : S47-50, 2012

 

5) Sugino K, et al. : Risk stratification of pediatric patients with differentiated thyroid cancer. Is total thyroidectomy necessary for patients at any risk? Thyroid 30 : 548-556, 2020

PubMed

6) Bien E, et al. : Pancreatoblastoma : a report from the European cooperative study group for paediatric rare tumours (EXPeRT). Eur J Cancer 47 : 2347-2352, 2011

 

7) Fridman M, et al. : Initial presentation and late results of treatment of post-Chernobyl papillary thyroid carcinoma in children and adolescents of Belarus. J Clin Endocrinol Metab 99 : 2932-2941, 2014

PubMed

8) Terris B, et al. : Diagnosis and molecular aspects of solid-pseudopapillary neoplasms of the pancreas. Semin Diagn Pathol 31 : 484-490, 2014

PubMed

9) Kerkhofs TM, et al. : Adrenocortical carcinoma in children : first population-based clinicopathological study with long-term follow-up. Oncol Rep 32 : 2836-2844, 2014

PubMed

P.588 掲載の参考文献

1) Mulliken JB, et al. : Hemangiomas and vascular malformations in infants and children : a classification based on endothelial characteristics. Plast Reconstr Surg 69 : 412-422, 1982

PubMed

2) Enjolras O : Classification and management of the various superficial vascular anomalies : hemangiomas and vascular malformations. J Dermatol 24 : 701-710, 1997

PubMed

3) International Society for the Study of Vascular Anomalies : ISSVA classification for vascular anomalies. International Society for the Study of Vascular Anomalies 2014 https://www.issva.org

 

4) Leaute-Labreze C, et al. : Propranolol for severe hemangiomas of infancy. N Engl J Med 358 : 2649-2651, 2008

PubMed

5) Zukerberg LR, et al. : Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am Surg Pathol 17 : 321-328, 1993

PubMed

6) Jones EW, et al. : Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol 20 : 214-225, 1989

PubMed

7) Uehara S, et al. : Intralesional sclerotherapy for subcutaneous venous malformations in children. Pediatr Surg Int 25 : 709-713, 2009

PubMed

8) Ozeki M, et al. : The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis 14 : 141, 2019

 

9) Morerio C, et al. : Differential diagnosis of lipoma-like lipoblastoma. Pediatr Blood Cancer 52 : 132-134, 2009

PubMed

巻末資料

P.598 掲載の参考文献

1) 日本小児血液・がん学会 (編) : 小児白血病・リンパ腫診療ガイドライン 2016年版. 2019. https://www.jspho.jp/journal/guideline.html (日本小児血液・がん学会), http://www.jsco-cpg.jp/childhood-leukemia/ (日本癌治療学会がん診療ガイドライン), https://minds.jcqhc.or.jp/n/med/4/med0107/G0000861 (Mindsガイドラインライブラリ)

 

2) 日本小児血液・がん学会 (編) : 小児がん診療ガイドライン 2016年版. 2016. https://www.jspho.jp/journal/guideline.html (日本小児血液・がん学会), http://www.jsco-cpg.jp/childhood-cancer/ (日本癌治療学会がん診療ガイドライン), https://minds.jcqhc.or.jp/n/med/4/med0090/G0000913 (Minds ガイドラインライブラリ)

 

3) 日本脳腫瘍学会 (編) : 2021年版 脳腫瘍診療ガイドライン. 2021. https://www.jsn-o.com/guideline/index.html

 

4) 日本放射線腫瘍学会, 日本小児血液・がん学会 (編) : 小児・AYA世代の腫瘍に対する陽子線治療診療ガイドライン 2019年版. 金原出版, 2019. https://www.jastro.or.jp/medicalpersonnel/guideline/aya_gl2019.pdf

 

5) 日本小児血液・がん学会組織球症委員会 (監) : 小児HLH診療ガイドライン. 2020. https://www.jspho.org/pdf/journal/hlh/hlh2020_v1.pdf

 

6) 小児遺伝性腫瘍研究班ガイドライン作成委員会 (編) : リー・フラウメニ症候群診療ガイドライン 2019. 2020. https://www.jspho.org/pdf/journal/li-fraumeni/li-fraumeni_1.pdf

 

7) 平成26-28年度厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 「難治性血管腫・血管奇形・リンパ管腫・リンパ管腫症および関連疾患についての調査研究」班 : 血管腫・血管奇形・リンパ管奇形診療ガイドライン 2017, 2017. https://www.marianna-u.ac.jp/va/guidline.html (難治性血管腫・脈管奇形・血管奇形・リンパ管腫・リンパ管腫症および関連疾患についての調査研究班), https://fb64b181-5dde-4de0-a3a2-f61925a989e2.filesusr.com/ugd/2a62b2_9e7d7fcffa394182b278e2afd782b764.pdf (血管腫・血管奇形・リンパ管奇形診療ガイドライン 2017)

 

8) 日本癌治療学会 (編) : 小児, 思春期・若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版. 金原出版, 2017. https://www.kanehara-shuppan.co.jp/books/detail.html?isbn=9784307301299

 

書評を投稿する